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Summary 
It is well accepted that we live in a modern industrialized environment that pushes the limit of our 
physiology and restricts our body to respond to additional stressors. This leads to a shifted 
vulnerability or resilience, depending on the individual genetic background and epigenetic factors, to 
the effects of stress which might result in the development of stress-related brain disorders like major 
depression. Understanding the cellular and molecular bases of stress-related mental disorders is crucial 
in the effort to develop new treatments, since treatment outcomes have improved only slightly in the 
past few decades. Only approximately 50% of patients with major depressive disorder show response 
to treatment after one treatment trial. The long duration required concluding treatment success or 
failure is a difficult and frustrating experience for the patient. Therefore, a current goal is moving 
towards the field of personalized medicine and biomarker research using patient specific profiles, with 
the perspective of providing more effective treatment.  
Evidence has been raised demonstrating the complex outcome of stress on the BDNF system and that 
the protein is a critical backbone in the functioning and well-being of the central nervous system. The 
protein is originally derived from the brain and related to neurotrophic actions which promote cell 
survival and development in the brain. Additionally, it is found in the periphery where it is stored in 
blood platelets and can be released into the serum. Several studies support the “neurotrophin 
hypothesis of depression”, which postulates that reduced brain levels of BDNF could contribute to 
atrophy and cell loss as observed in the hippocampus of depressed subjects. Until now several studies 
have demonstrated that stress causes impaired neurogenesis in brain structures, and that BDNF down-
regulation is one of the hallmark events that occur. However, the precise mechanism underlying this 
down-regulation has not been fully understood. Stress per se might not be sufficient to cause a 
psychiatric disorder like depression. It is believed that interactions between a genetic predisposition 
and environmental factors play a major role in the development of stress-related brain diseases. 
Furthermore, the BDNF regulation system seems to be very complex because of several influencing 
factors. Given that BDNF expression is decreased by stress and related to mood disorders, increased 
by antidepressants, and normalized in patients taking antidepressants, many investigators have focused 
on BDNF as a “biomarker” and potential target for treatment in major depression.  
 
The purpose of the present study was to elucidate the role of BDNF in stress related-brain disorders 
regarding the interplay of stress with the human homeostasis connected to sleep and prediction of 
therapy outcome. Therefore, we assessed systemic serum BDNF levels from human subjects. We 
could reveal that (1) there is a connection between sleep and serum BDNF levels, (2) sleep mediates 
the relationship between stress and BDNF and (3) a diurnal variation of serum BDNF levels is linked 
to favourable antidepressant treatment response. 
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(1) Sleep problems are common features in many stress-related mental disorders, problems that may 
lead to impairment of physical and mental health because sleep loss is often followed by higher stress 
vulnerability. Thus, insomnia is very common among depressed patients. Although a majority of 
studies have concentrated on specifying the role of BDNF in depression, the relation between BDNF 
and insomnia has not been a focus of recent research. Therefore, we investigated serum BDNF levels 
of subjects with current symptoms of insomnia and non-sleep disturbed controls including patients. 
We found subjective sleep impairment to be associated with lower serum BDNF levels, whereas 
reported good sleep was related to higher serum BDNF levels, as shown for those suffering from 
current insomnia compared with sleep-healthy subjects. Furthermore, serum BDNF levels were 
correlated with severity of insomnia in all participants. To confirm the relevance of this finding, we 
investigated an additional control sample recovered from occupational burnout after 12 weeks of 
aerobic exercise training. Again, serum BDNF levels were significantly lower in those reporting 
symptoms of fatigue compared with sleep-healthy subjects and were correlated with symptoms of 
tiredness and fatigue known to reflect malfunction of sleep. Hence, we suggest that serum BDNF 
levels are not associated with a specific diagnosis, but may be associated with insomnia symptoms 
independent of diagnosis. These results consolidate the awareness that when serum BDNF levels are 
analysed, insomnia symptoms should be carefully controlled, as well as improvements in sleep during 
therapy interventions in stress-related mood disorders. 
 
(2) However, the underlying mechanism in this relationship between sleep and BDNF has to be further 
elucidated. It might be possible that sleep impairment reflects a chronic stressor influencing the brain 
and in turn is accompanied by a deregulation of the HPA system, leading in the long term to decreased 
BDNF levels. Consequently, we wanted to reveal how stress and sleep could affect serum BDNF 
levels. Therefore we reanalysed the previous study were we could already demonstrate an association 
between decreased serum BDNF levels and insomnia severity (see [1]), by including further data. 
Remarkably, we could demonstrate an interaction between stress and insomnia with an impact on 
serum BDNF levels. With regard to insomnia severity, we divided all participants into three subgroups 
reflecting their score on the Insomnia severity Index: subjects with no insomnia, sub-threshold 
insomnia and clinical insomnia. Insomnia severity groups and stress each exhibited a significant main 
effect on serum BDNF levels. Furthermore, insomnia severity was associated with increased stress 
experience affecting serum BDNF levels. Notably, the association between stress and BDNF was only 
observed in subjects without insomnia. Searching for an explanation in the interplay between stress, 
sleep and BDNF we used a mediation model, which identified sleep as a mediator of the association 
between stress and serum BDNF levels. Here we could show for the first time that the interplay 
between stress and sleep impacts BDNF levels suggesting an important role of this relationship in the 
pathology of stress-related brain disorders. These basic findings support the role for sleep as key 
mediator at the connection between stress and BDNF. We propose the hypothesis that whether sleep is 
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maintained or disturbed might explain why some individuals are able to handle a certain stress load 
while others develop a mental disorder. 
 
(3) Finally, we complemented our previous work by investigating serum BDNF levels within a 
therapeutic intervention setting focussing on the association between BDNF and depressive symptoms 
as well as prediction of treatment response. Patients suffering from major depressive disorder, naïve to 
sleep therapy experienced a partial sleep deprivation (PSD) supplementary to an on-going mono-
therapy with mirtazapine. For serum sampling blood was obtained at seven different time points: at 
8am (t1), 2pm (t2) and 8pm (t3) for baseline (day 0), at 1.30am (t4) during PSD, as well as 8am (t5), 
2pm (t6) and 8pm (t7) after PSD (day 1).We could show that serum BDNF levels followed a diurnal 
pattern during the day before therapy intervention at baseline with high levels peaking in the morning 
and decreasing throughout the day. This diurnal pattern on the day before PSD was associated with an 
acute antidepressant treatment response since diurnal variation in serum BDNF was absent in non-
responders. Responders of the day after PSD revealed significantly increased serum BDNF levels in 
combination with a prominent diurnal variation of BDNF levels at baseline before PSD compared to 
non-responders. Notably, the same was also relevant for long-term responders, who showed an 
improvement of depressive symptoms after two weeks of on-going treatment. Again, day 14 non-
responders did not show this diurnal variation of BDNF levels. BDNF levels maintained at the same 
low level throughout the day, resulting in a flat line. In addition, serum BDNF levels were increased 
for acute and long-term responders at the day after PSD when compared to non-responders. This 
increase in BDNF levels on the day after PSD was correlated with improved mood and relaxation after 
a recovery night. In addition, the improvement of depressive symptoms after two weeks of on-going 
treatment was correlated with an increase of serum BDNF levels in all patients. Hence, our results 
indicate that the elasticity in diurnal serum BDNF variation is associated with favourable treatment 
response to PSD in patients suffering from MDD. Therefore, a normalized BDNF serum profile which 
oscillates in a circadian fashion seemed to precede, rather than follow a favourable treatment outcome 
in depressed patients. Thus, we suggest that diurnal profiling of BDNF should be monitored at 
baseline especially before therapeutic intervention starts for the purpose of early response prediction. 
 
In summary, our work demonstrates that sleep is associated with serum BDNF levels. This interplay is 
also influenced by stress and we could show that sleep is a mediator in the relationship between stress 
and BDNF. Therefore sleep, stress and BDNF seem to accomplish an important relationship in the 
pathology of stress-related brain disorders. Furthermore, we show that a diurnal variation of serum 
BDNF levels during the day before therapy intervention is associated with antidepressive response. 
This diurnal variation might allow the prediction for becoming responder or non-responder to a given 
antidepressive therapy. Notably, our results support the awareness of assessing sleep and sleep 
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improvement next to a diurnal variability profile, when BDNF levels are analysed, to promote 
antidepressive therapy and individual, personalized treatment. 
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A. Introduction 
The brain and body continuously adapt. In recent years the responsiveness of the price that body and 
brain have to pay in a „24/7‟ society have been grown, where social and physical environment have an 
enormous impact on physical and mental well-being (McEwen and Gianaros 2010). This modern 
industrialized society pushes the limit of our physiology and in turn restricts the capacity of the brain 
and body to respond to additional stressors. As a result, the brain is rendered to be more vulnerable or 
resilient, depending on an individual genetic background and epigenetic factors, to the effects of stress.  
Observing pathological alterations of brain structure and function remains markedly more difficult 
(Krishnan and Nestler 2008) than compared to other organs. Even with a long history of research in 
this field, the control of mood is still not solved and the development of efficient drugs is far from 
being satisfactory (Rush and Thase 1997; Kelly and Leonard 1999; Ioannidis 2008). Until now, studies 
on humans rely on occasions in which certain brain structures are absent – accidently or not – or on 
post-mortem tissues. Most diagnosis of brain disorders like depression, schizophrenia, anxiety or other 
stress-related alterations, in common named stress-related mood disorders, are subjective and rely on 
the documentation of a number of symptoms that significantly impair brain functioning for certain 
duration. This symptom-based diagnostic approach is accompanied by evident difficulties since 
diagnostic criteria might overlap with different conditions and disease patterns, since co-morbidity is 
quite common. Therefore, neuropsychiatric brain disorders are the most disabling of all medical 
disorders. According to statistics from community studies in European Union (EU) countries, Iceland, 
Norway and Switzerland 27% of the adult population (18-65 years) have been experienced at least one 
of a series of mood disorders in the past year, with an estimation of 83 million people being affected 
(WHO, 2013). Mood disorders frequently appear in life, run a chronic course and adversely affect the 
prognosis of other medical illnesses (Charney and Manji 2004). In the WHO European Region mental 
health problems affect one in four people at some time in life. Each year, 25% of the population suffer 
from depression or anxiety disorder and about 50% of major depressions are untreated. About 123.800 
people commit suicide with a mood disorder background every year. The costs of mood disorders in 
the EU are about 170 EUR billion per year (WHO, 2013). 
Understanding the cellular and molecular bases of these disorders is crucial in the effort to develop 
new treatments. Despite progress in understanding the neurobiology of brain disorders, treatment 
outcomes have improved only slightly in the past few decades even if broadening the target spectrum 
of pharmaceuticals, especially antidepressants. Only approximately 50% of patients with major 
depressive disorder (MDD) show response to treatment after one treatment trial, and only 30% of 
patients reach full remission (Weizman, Gonda et al. 2012). There is a significant decrease in the 
remission rate after four treatment trials (Rush, Trivedi et al. 2006). The long duration required 
concluding treatment success or failure (eight to twelve weeks) is a difficult and frustrating experience 
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for the patient (Sadock 2007). Besides failure to reach remission, the relapse rate is over 40%, 
especially in patients who did not achieve full remission (Zisook, Ganadjian et al. 2008; Sinyor, 
Schaffer et al. 2010). Therefore, a current goal is moving towards the field of personalized medicine 
and biomarker research with patient-specific profiles incorporating genetic and genomic data, as well 
as clinical and environmental factors, with the perspective of providing more effective treatment 
individually designed to a given patient or sub-population (Crisafulli, Fabbri et al. 2011; Porcelli 
2011).  
A.1 Neurotrophins 
Neurotrophins are considered to play a pivotal role in various aspects of neural function including 
survival, development, function, and activity-dependent synaptic plasticity. The influence of 
neurotrophins enfolds developmental neurobiology to neurodegenerative, and psychiatric disorders. 
As first neurotrophin, nerve growth factor (NGF) was identified, which was found during a search for 
such survival factors (Levi-Montalcini 1966).  
The surprising discovery that neurotrophins and their receptors do not exist in Drosophila 
melanogaster or Caenorhabditis elegans reinforce the idea that these proteins are not absolutely 
necessary for the development of neuronal circuits per se, but are involved in somehow higher-order 
activities (Chao 2003). In the mammalian brain, four neurotrophins have been identified: NGF, brain-
derived neurotrophic factor (BDNF) (Barde, Edgar et al. 1982), neurotrophin-3 (NT-3), and 
neurotropin-4 (NT4) (Hohn, Leibrock et al. 1990). All of these are considered to originate from a 
common ancestral gene, exhibit similarities in sequence and structure, and are therefore collectively 
named neurotrophins (Huang and Reichardt 2001). These closely related, highly basic proteins act by 
binding to two distinct classes of transmembrane receptors: the p75 neurotrophin receptor (p75
NTR
), a 
member of the tumour necrosis factor (TNF) receptor superfamily (Chao 2003), and the family of 
tropomyosin-related receptor tyrosine kinases (Trks), which include TrkA, TrkB and TrkC (Kaplan 
and Miller 2000; Dechant and Barde 2002; Chao 2003; Huang and Reichardt 2003). Like other 
secreted proteins, neurotrophins arise from precursors, pro-neurotrophins (30-35kDa), which are 
proteolytically cleaved to produce mature proteins (12-13kDa) (Seidah, Benjannet et al. 1996). Pro-
neurotrophins bind with high affinity to p75
NTR
, which for years was considered to be a low-affinity 
receptor. Of note, all neurotrophins bind to p75
NTR
 with a very similar affinity (Rodriguez-Tebar, 
Dechant et al. 1991) but mature neurotrophins selectively interact with their individual high-affinity 
protein kinase receptors. This interaction leads to cell survival, whereas binding of pro-neurotrophins 
to p75
NTR
 is involved in apoptosis (Lu, Pang et al. 2005).  
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Figure 1: BDNF signalling pathways. Mature BDNF forms a dimer and binds TrkB with high affinity to 
induce its dimerization and autophosphorylation of tyrosine residues in the cytoplasmic kinase domain. These 
residues serve as docking sites for effector molecules and trigger the activation of three main signalling 
pathways: PLCγ, PI3K and ERK cascades. These lead to phosphorylation and activation of the transcription 
factor CREB mediating transcription of genes essential for the survival and differentiation of neurons. The 
recruitment of PLCγ increases intracellular Ca2+ levels and leads to activation of CaMKII to phosphorylate 
CREB. PI3K can be activated via the Shc/Grb2/SOS complex through Gab1 and by IRS1/2. Lipid products 
generated by the activated PI3K, the phosphatidylinositides bind and activate protein kinase Akt, upstream of 
CREB. The ERK cascade can be activated both by Shc/Grb/SOS complex and by PI3K. ERK phosphorylation 
leads directly to CREB phosphorylation. PLCγ – phospholipase Cγ, PI3K – phosphatidylinositol 3-kinase, 
ERK – extracellular signal-regulated kinase, CaMKII – calcium-calmodulin dependent kinase, Shc – src 
homolgy domain containing, Grb2 – growth factor receptor-bound protein 2, SOS – son of sevenless, Gab1 – 
Grb-associated binder 1, IRS1/2 – insulin receptor substrates 1/2, CREB – cAMP-calcium response element 
bidning protein, Ras – GRP binding protein, Raf – Ras associated factor, MEK – MAP/Erk kinase (adapted 
from Cunha (Cunha, Brambilla et al. 2010)). 
A.2 BDNF cell biology  
BDNF and related family members influence the proliferation, differentiation, and growth of neurons 
during development, but are also expressed in the adult brain and play a critical role in the survival 
and function of mature neurons (McAllister 2002). The protein is moderately sized and charged with 
an isoelectric point about Ip≈10.1, which indicates the strong basicity (Barde, Edgar et al. 1982). 
Furthermore it is characterised by a high specific activity of 0.4ng/ml per unit (1 unit defines the 
protein concentration in ng/ml, where 50% of neurons survive in cell culture) or rather 3x10
11
M 
(Barde, Edgar et al. 1982). BDNF is expressed at high levels in limbic brain structures implicated in 
mood disorders, including the hippocampus, prefrontal cortex (PFC), and amygdala. Cellular actions 
of BDNF are mediated through Trk receptor type B and p75
NTR
. The p75
NTR
 was shown to transmit 
signals important for determining which neurons survive during development. Functional, mature 
BDNF is a polypeptide of 119 amino acids, about 14kDa in size, forms stable, non-covalent dimers 
(28kDa) (Barde, Edgar et al. 1982; Mowla, Farhadi et al. 2001; Lessmann, Gottmann et al. 2003) and 
has been shown to directly bind and dimerize TrkB receptors stimulating autophosphorylation of 
specific tyrosine residues present in their cytoplasmic kinase domains, present on the cellular 
membrane of receptive cells in the central nervous system (Greenberg, Xu et al. 2009).  
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This results in activation in one of three major intracellular signalling cascades: the mitogen-activated 
protein kinase (MAPK, or extracellular signal related kinase ERK) which activates several 
downstream effectors; the phosphatidylinositol-3 kinase (PI3K) which activates serine/threonine 
kinase AKT; and the phospholipase-C- γ (PLCγ) pathway which leads to activation of protein kinase C 
(Tanis, Newton et al. 2007) (Figure 1). BDNF is a glycoprotein and secreted in response to neuronal 
activity, largely via the regulated pathway and derived from both pre-and postsynaptic sites 
(Waterhouse and Xu 2009). The action of BDNF signalling on synapses arises within seconds of 
stimulation or application/release of the factor (Kovalchuk, Holthoff et al. 2004) and results in 
sustained TrkB activation. In brief, rapid synaptic and ion channel effects are thought to depend on 
PLCγ-mediated release of intracellular calcium stores, and longer-lasting effects involving 
transcription are considered to be downstream of PI3K and MAPK pathways (Autry and Monteggia 
2012). These cascades have been linked to neuroprotective effects of BDNF, as well as regulation of 
cell proliferation, differentiation, and survival (McAllister 2002). 
Next to the central nervous system BDNF is also found in the periphery and therefore has been of 
particular interest, because of its potential role in non-neuronal tissues. BDNF mRNA has been found 
for example in the rat aorta (Scarisbrick, Jones et al. 1993), kidney, submandibular gland, ovary, 
dorsal root ganglia (Ernfors, Wetmore et al. 1990), heart (Hiltunen, Arumae et al. 1996), retina, 
muscle, lung (Maisonpierre, Belluscio et al. 1990; Maisonpierre, Le Beau et al. 1991), T and B 
immune cells (Kerschensteiner, Gallmeier et al. 1999), endothelial cells and platelets (Yamamoto and 
Gurney 1990). The TrkB receptor is present in peripheral targets including vascular endothelial cells 
(Donovan, Lin et al. 2000), vascular smooth muscle (Nemoto, Fukamachi et al. 1998), dorsal root 
ganglia neurons (McMahon, Armanini et al. 1994), Schwann cells (Alderson, Curtis et al. 2000), B 
(D'Onofrio, de Grazia et al. 2000) and T (Maroder, Bellavia et al. 1996) lymphocytes, and endocrine 
cells (Esteban, Hannestad et al. 1995). It has been shown that activated human T and B cells, and 
monocytes (Kerschensteiner, Gallmeier et al. 1999) produce BDNF and express truncated (Besser and 
Wank 1999) as well as full-length (Maroder, Bellavia et al. 1996; D'Onofrio, de Grazia et al. 2000) 
TrkB receptors on their cell surface.  
The existence and function of BDNF in blood, particularly serum and plasma of humans and other 
mammals are poorly understood (Fujimura, Altar et al. 2002; Mori, Shimizu et al. 2003). Blood 
platelets are the major storage side of BDNF in blood, from which it can be released into the plasma 
through activation or clotting processes (Fujimura, Altar et al. 2002). After agonist stimulation during 
blood coagulation, roughly half of the BDNF contained in platelets is released at the site of injury 
(Burnouf, Kuo et al. 2012). The contribution of alternative sources of blood BDNF like endothelial 
cells (Nakahashi, Fujimura et al. 2000) and lymphocytes is believed to be marginal compared with the 
bulk release from platelets. Extracts from platelets contain 50 to 100 times the BDNF biologic activity 
of brain extract (Yamamoto and Gurney 1990). Human serum contains BDNF at far greater 
concentrations, which is about 100-fold higher (approximately 10-27ng/ml) compared to human 
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plasma (Rosenfeld, Zeni et al. 1995; Radka, Holst et al. 1996; Fujimura, Altar et al. 2002; Burnouf, 
Kuo et al. 2012) due to the fact that in serum a total, including the amount of BDNF released from the 
platelets, is detected. It has been suggested that almost all of the BDNF in serum originates from 
platelets and that freely circulating BDNF in blood binds to the surface of platelets, which could 
promote the internalization of BDNF through as yet unidentified binding sites that appear to be 
distinct from TrkB or p75 receptors (Fujimura, Altar et al. 2002). It is also suggested that platelets may 
serve as a reservoir for circulating BDNF (Fujimura, Altar et al. 2002). The absence of nuclei and lack 
of platelet protein synthesis is consistent with a dependence upon circulating BDNF. Furthermore, it 
was shown in a cell culture model that BDNF in platelets does not originate from megakaryocyte 
precursor cells of mature platelets (Fujimura, Altar et al. 2002). It is more likely, that the presence of 
BDNF in platelets results from both synthesis by vascular endothelial cells (Nakahashi, Fujimura et al. 
2000) and internalization from blood circulation (Fujimura, Altar et al. 2002), rather than from in situ 
platelet synthesis because they contain only small to no amounts of BDNF mRNA probably derived 
from the cytoplasm of megakaryocytic (Yamamoto and Gurney 1990) cells, precursors of platelets, 
and megakaryocytes are believed to actually not contain BDNF (Fujimura, Altar et al. 2002). The 
reason why platelets are the major storage side of peripheral blood BDNF is not clear. A hypothesis, 
which has been suggested, deals with the assumption that platelets provide an important source of 
BDNF for regenerating peripheral sensory neurons at the site of nerve injury (Fujimura, Altar et al. 
2002). 
Platelet BDNF content can change rapidly, suggesting that they are a dynamic repository of BDNF in 
peripheral blood and are able to release BDNF under certain physiologic requirements (Lommatzsch, 
Niewerth et al. 2007). The ability of BDNF to cross the blood-brain barrier has been demonstrated 
(Pan, Banks et al. 1998), suggesting that serum BDNF levels may reflect levels in the brain. Despite 
the presumption of a short half-life in the plasma, the interest remains in the possible ability of BDNF 
to cross the blood-brain barrier in certain physiologic conditions (Pan, Banks et al. 1998; Schabitz, 
Steigleder et al. 2007). A recent study has demonstrated that in rats BDNF crosses the blood-brain 
barrier from brain to periphery and vice versa, since BDNF brain tissue and serum concentrations have 
been positively correlated (Sartorius, Hellweg et al. 2009). The authors even speculate that a main 
portion of elevated serum BDNF after electroconvulsive treatment has been derived from the brain 
with a time delay of three to seven days to establish an equilibrium again (Sartorius, Hellweg et al. 
2009). Due to size and charge of BDNF it is possible that only a minimal amount might cross the 
blood-brain barrier via peripheral administration (Neto, Borges et al. 2011). On the other hand 
peripheral BDNF levels may only give an indirect hint on effective BDNF concentrations in the CNS. 
However, in principle a correlation of peripheral BDNF with cortical BDNF levels has been shown in 
studies with rats (Karege, Schwald et al. 2002). Furthermore, after peripheral administration in mice 
BDNF has been stable in circulating blood for 60 minutes and crossed the blood brain barrier via 
influx. It has been suggested that this rapid, saturable influx occurs through a specific transport system 
  A. Introduction 
6 
(Pan, Banks et al. 1998). Until now, this finding has not been replicated and there is no study reporting 
a distinct possible transporter or transport mechanism for BDNF from blood to brain. 
A.2.1 Transcription, trafficking, secretion and cleavage 
The Bdnf gene is located on the short (p) arm of chromosome 11 at position 13 (11p13) and its 
genomic structure is quite complex. BDNF is the result of translation of at least 34 mRNA transcripts 
produced by alternative splicing of 11 upstream exons (exon 1-9a). Each of these exons code for the 
5´untranslated region (5´UTR), linked to individual promoter regions. Splicing leads to a common 
downstream exon 9 (Figure 2) that encodes the BDNF pre-protein amino acid sequence and two 
different 3´UTR sequences (Pruunsild, Kazantseva et al. 2007). The transcription of each exon is 
driven by separate promoters in turn controlled by an array of signalling mechanisms, for example 
calcium, cAMP response element-binding protein (CREB) and hormones (Lu, Pang et al. 2005; 
Molteni, Calabrese et al. 2009). Furthermore, it has been demonstrated that the account of specific 
BDNF splice variants is controlled by a variety of epigenetic mechanisms, including DNA methylation 
and posttranslational modifications of histones (Lubin, Roth et al. 2008; Roth, Lubin et al. 2009). The 
regulation of specific promoters causes the temporal and spatial expression of specific BDNF 
transcripts (Lauterborn, Rivera et al. 1996), some of which can undergo trafficking and targeting to 
dendrites (Chiaruttini, Sonego et al. 2008). 
Initially synthesized as proform (pro-BDNF) it is either cleaved into the mature (m-BDNF) 
neurotrophin or transported to the plasma membrane and released in an unprocessed manner.  
After synthesis in the endoplasmatic reticulum, pro-neurotrophins need to be folded correctly, sorted 
into the constitutive or regulated secretory pathway, and transported to the appropriate subcellular 
compartment (Lu, Pang et al. 2005). The pro-domain of BDNF binds to sortilin, a receptor that is 
mainly intracellular (Petersen, Nielsen et al. 1997; Nielsen, Madsen et al. 2001) and controls the mode 
                            
Figure 2: Illustration of the human Bdnf gene structure and its splicing variants. Exons are indicated by 
blue boxes. Dotted box in exon 9 indicates the coding region of the Bdnf gene. Arrows indicate alternative 
polyadenylation sites (Poly A) in the 3‟UTR and internal alternative splice sites in exons 2, 6, 7 and 9a (letters a, 
b, c and d). The Bdnf gene is transcribed from different promoters, immediately preceding each of the 5‟ exons, 
that each full-length transcript contains a unique 5‟ exon and common 3‟ exon that contains the BDNF coding 
sequence (CDS). (adapted from Baj and Tongiorgi (Baj and Tongiorgi 2009)). 
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of secretion (Chen, Ieraci et al. 2005), in the Golgi to facilitate proper folding of the mature domain. 
Sortilin is co-localized with BDNF in secretory granules in neurons, and interacts with two sub-
regions: box 2, containing the Val66 amino acid and box 3, both of which are in the pro-domain of 
BDNF (Lu, Pang et al. 2005). A motif in the mature domain of BDNF binds to the sorting receptor 
carboxypeptidase E (CPE). This interaction sorts BDNF into large dense core vesicles (LDCVs), a 
component of the regulated secretory pathway. In the absence of this motif, BDNF is sorted into the 
constitutive pathway. After binary decision of sorting, BDNF is transported to the appropriate site of 
release, either in dendrites or in axons. In some cases the pro-domain is not intracellularly cleaved by 
furin or protein convertases and therefore released as pro-BDNF by neurons. Extracellular proteases, 
such as metalloproteinases and plasmin can subsequently cleave the pro-region to yield mature BDNF 
(Schweigreiter 2006). Many non-neuronal cells, such as smooth muscle cells, fibroblasts and 
astrocytes, may not express molecular components of the regulated secretory pathway and, therefore, 
secrete neurotrophins only constitutively (Lu, Pang et al. 2005). Regulated secretion is prevalent in 
neurons. Neurotrophin-containing secretory granules are transported to dendrites and spines, and 
secreted postsynaptically. On the other hand, neurotrohpin-containing LDCVs undergo anterograde 
transport to axonal terminals. Either pro-neurotrophins are intracellularly cleaved, followed by 
secretion, or secreted and followed by extracellular cleavage, but the extent of intracellular and 
extracellular processing of pro-BDNF is not exactly clear. However, pro-BDNF is less efficiently 
processed by intracellular proteases compared to other neurotrophins and secretion of pro-BDNF with 
respect to m-BDNF seems to prevail (Mowla, Farhadi et al. 2001). Another possibility is the secretion 
without subsequent cleavage (Lu, Pang et al. 2005). In addition to interacting with p75
NTR
, secreted 
pro-neurotrophins might be degraded extracellular.  
A.3 Stress, BDNF and mood disorders  
In the 1930s, the term stress was lent from engineering: a measure of internal forces acting within a 
deformable body, by Hans Selye. In his translation to biology, he defined stress as the result of an 
organism´s failed attempt to respond appropriately to a physical challenge (Selye 1998). Since then, 
this definition has been elaborated to include physiological threats (Schulkin, McEwen et al. 1994). 
Furthermore, the pioneering work of John Mason on psychological stress (Mason 1959) has permeated 
both modern psychology and neuroscience.  
Nowadays, stress is used as a model to study alterations of brain structure and function because mood 
disorders are often caused or exacerbated by acute or chronic stressful life events (Gold and Chrousos 
2002). Therefore, stress paradigms have long been used to model these diseases. Physical or 
psychological stress increases serum glucocorticoid concentrations. In rodents depression-like 
symptoms can be produced by chronic administration of glucocorticoids (Gourley, Wu et al. 2008). A 
prominent mechanism by which the brain reacts to acute and chronic stress is activation of the 
hypothalamic-pituitary-adrenal (HPA) axis (Figure 3)  
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Neurons in the paraventricular nucleus (PVN) of the hypothalamus secrete corticotropin-releasing 
factor (CRF), which stimulates the synthesis and release of adrenocorticotropin (ACTH) from the 
anterior pituitary gland. ACTH then stimulates the synthesis and release of glucocorticoids (cortisol in 
humans and corticosterone in rodents) from the adrenal cortex (Figure 3). Glucocorticoids exert 
profound effects on general metabolism and also dramatically affect behaviour via direct actions on 
numerous brain regions. Several brain pathways, including the hippocampus via an inhibitory 
influence on the hypothalamic CRF-containing neurons and the amygdala, control the activity of the 
HPA axis.  
Glucocorticoids, by potently regulating hippocampal and PVN neurons, exert powerful feedback 
effects on the HPA axis. Under normal physiological (McEwen 2000) conditions glucocorticoids seem 
to enhance hippocampal inhibition of HPA activity and even enhance hippocampal function in 
general, thereby promoting certain cognitive abilities (Nestler, Barrot et al. 2002). But, sustained 
elevations of glucocorticoids, seen under conditions of prolonged and severe stress, may damage 
hippocampal neurons (Nestler, Barrot et al. 2002), involve a reduction in dendritic branching and a 
loss of highly specialized dendritic spines where neurons receive their glutamatergic synaptic inputs 
(McEwen 2000; Sapolsky 2000).  
Stress and the resulting hypercortisolemia can be manifested at several levels including i) impaired 
glucocorticoid-receptor-mediated negative feedback (Brown, Varghese et al. 2004), ii) adrenal hyper-
                      
Figure 3: Regulation of the HPA axis. CRF-containing neurons of the hypothalamic PVN integrate 
information relevant to stress. The factor is released by these neurons into the hypophyseal portal system and 
acts on the anterior pituitary gland to release ACTH. This reaches the adrenal cortex via the bloodstream, where 
it stimulates the release of glucocorticoids (cortisol). In turn glucocorticoids repress CRF and ACTH synthesis 
and release and inhibit their own synthesis. At higher levels, glucocorticoids also impair, and may even damage, 
the hippocampus, which could initiate and maintain a hypercortisolemic state. PVN – paraventricular nucleus, 
CRF – corticotropin-releasing factor, ACTH – adrenocorticotropin (adapted from Nestler (Nestler, Barrot et al. 
2002)). 
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responsiveness to circulating ACTH (Parker, Schatzberg et al. 2003), iii) hyper secretion of CRF 
(Nemeroff and Owens 2002) and iv) the hypothalamic activator of ACTH release from the pituitary 
(de Kloet, Joels et al. 2005). As a result the inhibitory control that the hippocampus exerts on the HPA 
axis is reduced, which would further increase circulating glucocorticoid levels and subsequently 
damage the hippocampus in a positive feedback manner (Nestler, Barrot et al. 2002). Deregulation or 
hyperactivity of the HPA axis is one of the most prominent findings in up to 70% of patients with 
major depressive disorder (Porcelli 2011).  
However, stress per se is not sufficient to cause a mood disorder like depression. Most people do not 
become depressed after serious stressful experiences, whereas some others do become depressed after 
stress that for most people is quite mild (Nestler, Barrot et al. 2002). This underscores, that stress 
associated mood disorders are caused by interactions between a genetic predisposition and 
environmental factors. A modulation of BDNF by stress was originally shown several years ago 
(Smith, Makino et al. 1995). Since then, evidence has been produced demonstrating the complex 
outcome of stress on the BDNF system and that the protein is a critical backbone in the functioning 
and well-being of the central nervous system.  
Until now, several studies have demonstrated that stress causes impaired neurogenesis and atrophy in 
certain limbic structures, and that BDNF down-regulation is one of the events that occur. However, the 
precise mechanism underlying this down-regulation has not been fully understood. There is evidence 
that stressful experience decreases levels of specific BDNF isoforms, transcripts III and IV, associated 
with robust chromatin modification (Tsankova, Berton et al. 2006; Molteni, Calabrese et al. 2009) and 
therefore might contribute to atrophy of limbic structures, including the hippocampus, observed in 
depressive patients (Bremner, Narayan et al. 2000). Since the BDNF regulation system seems to be 
very complex because of several influencing factors, it has been suggested that glucocorticoids 
modulate BDNF signalling pathways. It is known that high adrenal-glucocorticoid levels, the hallmark 
endocrine response to stress, decrease BDNF expression. The hippocampus receives input from the 
HPA axis modulating stress responses and is important in emotional cognition and memory (McEwen 
2005). BDNF and TrkB levels are decreased in regions of the hippocampus in post-mortem tissue 
taken from suicide victims, patients with major depressive disorder (MDD) or in the serum of MDD 
patients (Castren, Voikar et al. 2007; Castren and Rantamaki 2010; Thompson Ray, Weickert et al. 
2011). Given that BDNF expression is decreased by stress, structural changes in the hippocampus 
related to MDD may be attributed in part to the reductions in BDNF and TrkB (Yu and Chen 2011).  
Another region, the prefrontal cortex, essential to emotional processing, has been examined in relation 
to pathological features of MDD. In humans suffering from depression, this brain region has also been 
decreased in volume, correlated with lower BDNF and TrkB levels (Dwivedi, Rizavi et al. 2003; 
Castren 2004; Pandey, Ren et al. 2008). Paradoxical, BDNF expression is enhanced in other areas of 
the brain. Studies revealed that BDNF is increased in the nucleus accumbens (NAc) from human 
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patients with MDD (Krishnan, Han et al. 2007). Further findings suggest that BDNF is enhanced in 
the amygdala in response to stress (Yu and Chen 2011). 
A.3.1 Major depressive disorder 
Depression affects a huge number of people worldwide. Principal symptoms observed in depressed 
patients deal with loss of interest or pleasure, feelings of guilt or worthlessness, disturbed sleep or 
appetite, low energy, poor concentration and suicidal intentions (Fava and Kendler 2000; Nestler, 
Barrot et al. 2002). This unpleasant „state of mind“ may be related with working conditions, self-
perceived stress, anxiety and quality of life (Rusli, Edimansyah et al. 2008). However, it is curious 
why predisposition to develop a depression is higher in certain persons than in others. Today, it is 
assumed that a complex interaction between genetic, biochemical and environmental factors may be 
underlying the causative aetiology of this disorder (Nestler, Barrot et al. 2002). Epidemiologic studies 
show that roughly 40-50% of the risk for depression is genetic (Sanders 1999; Fava and Kendler 
2000), including the fact that depression is a complex phenomenon with many genes possibly 
involved. In addition, vulnerability to depression is only partly genetic, with non-genetic and 
epigenetic factors also being important.  
Several brain regions and circuits regulate emotion, reward and executive function. Dysfunctional 
changes within these highly interconnected limbic regions have been implicated in depression and 
antidepressant action (Berton and Nestler 2006). The monoamine hypothesis of depression was the 
most accepted by the scientific community (Hirschfeld 2000; Van Praag 2001; Owens 2004). This 
hypothesis has been based on the acceptance that the illness is caused by a deficit in the 
neurotransmission of serotonin and noradrenalin and that it could be reversed by drugs – namely 
antidepressants – that promote increase of these neurotransmitters in the synaptic cleft (Hyman 1993; 
Hindmarch 2002; Krishnan and Nestler 2008). However, this theory was not sufficient to explain the 
pathological mechanisms underlying depression. Antidepressants promote an immediate increase of 
serotonin and noradrenaline transmission acting either by blockage of the reuptake of monoamines, or 
by inhibition of their degradation at the synaptic cleft (Hindmarch 2002; Krishnan and Nestler 2008). 
Of note, the antidepressant effect is usually only observed after a few weeks of treatment adaptation, 
since several neurotransmitter systems next to downstream serotonergic or noradrenergic signalling 
pathways might be involved and are responsible for antidepressant efficacy. Interestingly, monoamine 
depletion studies demonstrate decreased mood in subjects with a family history of major depression 
(MD) and in drug-free patients with MD in remission, but do not decrease mood in healthy humans 
(Delgado, Price et al. 1991; Ruhe, Mason et al. 2007). Therefore, it becomes obvious that depression 
involves further modifications besides initial effects those at the monoamine system. 
A.3.2 The neurotrophic hypothesis of depression 
Over the past 10 years, molecular and cellular studies of stress, depression and antidepressants have 
moved the field of mood disorder research beyond the monoamine hypothesis of depression. These 
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studies demonstrate that stress and antidepressant treatment exert opposing actions on the expression 
of specific neurotrophic factors in limbic brain regions involved in the regulation of mood and 
cognition. Volumetric decreases observed in the hippocampus and other forebrain regions in subsets of 
depressed patients have supported a popular hypothesis for depression involving the decrease of 
neurotrophic factors (Monteggia, Barrot et al. 2004; Duman and Monteggia 2006). Many animal 
studies have also documented that stress reduces the expression of BDNF mRNA in the hippocampus 
(Smith, Makino et al. 1995; Duman and Monteggia 2006). Conversely, numerous classes of chemical 
antidepressants, as well as other forms of therapeutic interventions like electroconvulsive shock 
treatment and sleep deprivation, can significantly increase BDNF mRNA expression in hippocampus, 
prefrontal cortex or both of rodents (Nibuya, Morinobu et al. 1995; Russo-Neustadt, Beard et al. 2000; 
Duman and Monteggia 2006). This increase depends on chronic antidepressant treatment as shown in 
rats (Nibuya, Morinobu et al. 1995), which is consistent with the slow onset of therapeutic effects of 
antidepressants in a clinical setting. Furthermore, limited studies have shown that direct hippocampal 
infusion of BDNF protein can produce antidepressant effects in rodents (Siuciak, Lewis et al. 1997; 
Shirayama, Chen et al. 2002). These studies support the “neurotrophin hypothesis of depression”, 
which postulates that reduced brain levels of BDNF could contribute to atrophy and cell loss in the 
hippocampus and prefrontal cortex, as observed in depressed subjects. Antidepressants may exert their 
therapeutic effects by increasing BDNF expression, thereby leading to the reversal of neuronal atrophy 
and cell loss (Duman and Monteggia 2006). The reduction of BDNF appears to be mediated partly via 
stress-induced glucocorticoids and partly via other mechanisms, such as stress-induced increases in 
serotonergic transmission (Smith, Makino et al. 1995; Vaidya, Marek et al. 1997). Compared to 
healthy human subjects, levels of BDNF are lower in post-mortem brain tissue from depressed patients 
but higher in those who were under antidepressant medication at the time of death (Chen, Dowlatshahi 
et al. 2001). Given that BDNF expression is decreased by stress and related to mood disorders, 
increased by antidepressants, and normalized in patients taking antidepressants, many investigations 
focused on BDNF as a “biomarker” and also a potential target for treatment of major depression. In 
sum, support for this BDNF hypothesis originates from large preclinical literature showing that several 
forms of stress reduce BDNF-mediated signalling in the hippocampus, whereas chronic treatment with 
antidepressants increases BDNF signalling (Nestler, Barrot et al. 2002; Duman and Monteggia 2006). 
Despite all these data, BDNF alone may not be sufficient to explain depression-related behaviours, but 
it remains an important risk factor. 
A.3.3 BDNF and antidepressants / mode of action 
The BDNF hypothesis predicts that agents that promote BDNF function might be clinically effective 
antidepressants. A causal role for the antidepressant action of BDNF has come from experiments in 
rodents in which antidepressant effects were observed on direct infusion of BDNF in the hippocampus 
(Shirayama, Chen et al. 2002) and were blocked on the conditional or inducible knockout of the gene 
encoding BDNF from forebrain regions (Monteggia, Barrot et al. 2004; Groves 2007). The time delay 
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for the therapeutic action of antidepressant treatment suggests that adaptations of receptor-coupled 
signal transduction proteins and their corresponding genes could contribute to the actions of 
antidepressants. BDNF modulation could be a key step in this adaptive process.  
It has been shown (Siuciak, Boylan et al. 1996) that infusion of BDNF either intracerebroventricularly 
or directly into the rat midbrain produced analgesia and, interestingly, increased the activity of the 
monoaminergic systems. Indeed, BDNF infusion promotes the function, sprouting and growth of 
serotonin-containing neurons in the brain of adult rats (Altar 1999) and increases noradrenaline levels 
in several brain areas including the hippocampus (Siuciak, Boylan et al. 1996). These effects of BDNF 
on serotonergic and noradrenergic systems link the classical monoaminergic hypothesis of depression 
with the neurotrophic theory. Further studies demonstrated that both acute or sub-chronic (3-7 days) 
BDNF infusion into the hippocampus (DG and CA3 layer) or in the midbrain, produces an 
antidepressant-like effect in two behavioural models of depression, the learned helplessness and the 
forced swimming test paradigms. However, this effect seems to be specific to certain brain areas 
because BDNF infusion into the ventral tegmental area (VTA) or in the nucleus accumbens (NAc), for 
example, increases depression-like behaviour. Interestingly, this behaviour is reversed by the 
inhibition of BDNF signalling producing an antidepressant-like effect (Eisch, Bolanos et al. 2003). 
These findings are in line with the stress-induced increase of BDNF expression in prefrontal cortex 
(PFC) (Lee, Duman et al. 2006) and are opposite to the effect observed in the hippocampus, 
suggesting that BDNF antidepressant effect is area-dependent. Consistent through the literature is the 
finding, that BDNF infusion in the hippocampus or/and the midbrain produces antidepressant-like 
behavioural effects and that most of clinically effective antidepressant drugs work through this 
mechanism. Post-mortem tissue studies demonstrate that BDNF levels are increased in the 
hippocampus and cortex after long-term antidepressant use. In addition, studies of serum BDNF levels 
are normalized in patients suffering from depression after long-term antidepressant treatment (Duman 
and Monteggia 2006), a finding that has been validated after meta-analyses of multiple studies (Sen, 
Duman et al. 2008). However, studies of BDNF in post-mortem tissue are correlative, and the exact 
origin and function of serum-derived BDNF remains unclear. The Bdnf gene is induced in vitro and in 
vivo by CREB (Tao, Finkbeiner et al. 1998; Conti, Cryan et al. 2002). Moreover, virtually all major 
classes of antidepressants increase levels of CREB expression and function in several brain regions 
including hippocampus (Nibuya, Morinobu et al. 1995). Indeed, BDNF increase has been reported for 
selective serotonin reuptake inhibitors (SSRIs), noradrenaline reuptake inhibitors (SNRIs) (dual-action 
and tricyclic antidepressants), with monoamine oxidase inhibitors (MAOIs), atypical antidepressants, 
as well as with electroconvulsive shock treatment, one of the most clinically effective treatments for 
refractory depression (Nibuya, Morinobu et al. 1995; Kuroda and McEwen 1998; Russo-Neustadt, 
Beard et al. 1999; Fukumoto, Morinobu et al. 2001; Coppell, Pei et al. 2003; Holoubek, Noldner et al. 
2004; Jacobsen and Mork 2004; Vinet, Carra et al. 2004; Song, Che et al. 2006; Garcia, Comim et al. 
2008; Garcia, Comim et al. 2009; Larsen, Mikkelsen et al. 2010). In addition to improve or just 
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modify signalling pathways, antidepressants may help critical systems to overcome challenging 
conditions regarding neuronal plasticity, which is required to cope and adapt to stressful situations. It 
has been reported that antidepressants appear to increase the tyrosine autophosphorylation of TrkB 
receptors, activate PLCγ signalling and subsequent phosphorylation of CREB (Castren, Voikar et al. 
2007). However, it is not clear how antidepressants modify BDNF levels. Probably the effects on 
BDNF are complex and may occur at several levels. It has been shown that changes of specific BDNF 
isoforms occur during antidepressant treatment (Molteni, Calabrese et al. 2009) that may contribute to 
an adequate response to stress. In conclusion, antidepressants may have a potential impact on activity-
dependent plasticity within regions involved in emotional processing, affected in depression. 
Antidepressants may promote neuroprotective pathways and render them more responsive to preserve 
cell functionality. However, current results from the literature compelled a revision of the hypothesis 
regarding the antidepressant action of BDNF. First, a substantial number of preclinical studies either 
failed to show these patterns of changes induced by stress and by antidepressants, or have shown the 
opposite effects (Groves 2007; Martinowich, Manji et al. 2007). Second, male mice with conditional 
forebrain deletions of BDNF or its receptor do not show depression-like behaviour (Zorner, Wolfer et 
al. 2003; Monteggia, Luikart et al. 2007). Third, in other regions, for example the VTA and the NAc, 
BDNF exerts a potent pro-depressant effect: chronic stress increases the amount of BDNF within the 
NAc (Berton, McClung et al. 2006), and direct infusion of BDNF into the VTA-NAc increases 
depression-related behaviours (Eisch, Bolanos et al. 2003; Krishnan, Han et al. 2007). Finally, the 
single-nucleotide polymorphism Val66Met, which impairs intracellular trafficking and activity-
dependent release of BDNF (Egan, Kojima et al. 2003; Chen, Jing et al. 2006) and decreases 
hippocampal volume (Szeszko, Lipsky et al. 2005; Chen, Jing et al. 2006) does not alter genetic 
vulnerability to depression (Gratacos, Gonzalez et al. 2007; Lopez-Leon, Janssens et al. 2008). 
Together these results suggest that the current formulation of the BDNF hypothesis is too simplistic. 
BDNF-mediated signalling is involved in neuroplasticity responses to stress and antidepressants, but 
these effects are both region-specific (Nestler and Carlezon 2006) and antidepressant-specific (Duman 
and Monteggia 2006). Of note, treatment with antidepressants, possibly through the actions of CREB 
or other transcriptional regulators (Nestler, Barrot et al. 2002; Pittenger and Duman 2008) increases 
the amounts of several growth factors, including BDNF (Sairanen, Lucas et al. 2005) in the 
hippocampus that influence neurogenesis. A marked cellular effect of several, but not all, 
antidepressant treatments is the induction of adult hippocampal neurogenesis (Sahay and Hen 2007; 
Pittenger and Duman 2008).  
A.4 Pre- and clinical evidences: BDNF de-regulation in psychiatric disorders 
Stress is a risk factor for major depression in vulnerable individuals. Basic research has used animal 
models, which imply stress to model such complex multi-syndrome psychiatric illnesses as partly 
aforementioned in paragraph A.3.2. Chronic stress is a generally accepted model of depression 
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because it leads to neurochemical and behavioural alterations that are analogous to those observed in 
depressed human patients, including increases in stress hormones, hippocampal atrophy, increased 
anxiety- and depression-related behaviours, and cognitive impairments (McEwen and Magarinos 
1997; Yan, Cao et al. 2010). In general, most of the studies have shown that acute or chronic stress 
induced by different types of stressors, such as immobilization, unpredictable foot shock, social 
isolation, social defeat, maternal deprivation, restraint and swim stress decrease BDNF levels in the 
hippocampus (Choy, de Visser et al. 2008).  
A.4.1 Animal models 
A.4.1.1 Transgenic BDNF mice 
Meanwhile multiple animal models of deficient BDNF signalling have been produced. Investigators 
generated heterozygous, conditional, and region-specific knockout or knockdown models to study 
depression-related behaviour in adult mice, since constitutive BDNF knockout mouse models show 
developmental brain abnormalities and die soon after birth (Ernfors, Lee et al. 1994). BDNF 
heterozygous mice reveal about 50% reduction of mRNA and protein throughout the animal. 
Furthermore, conditional and inducible genetic models have been developed to remove BDNF in a 
regionally and temporally dependent manner, to reduce profound changes in depression-related 
behaviour at later development (Chourbaji, Hellweg et al. 2004) and over the course of development 
for baseline-behaviour. In mouse models where BDNF is deleted from forebrain neurons later in 
development, there are no severe changes in depression-related behaviour (Monteggia, Barrot et al. 
2004), although female mice may display behavioural alterations in certain assays (Monteggia, Luikart 
et al. 2007). This may be explained, because with this type of deletion behavioural effects cannot be 
attributed to specific neural circuits (Autry and Monteggia 2012). Though, all of these lines of mice 
consistently display an inability to respond to antidepressant treatment, pointing towards an essential 
role for BDNF in the presence of behavioural antidepressant responses (Monteggia, Barrot et al. 2004; 
Malberg and Blendy 2005; Tardito, Perez et al. 2006; Monteggia, Luikart et al. 2007). To target 
specific brain regions, viral-mediated deletion techniques are used to delete BDNF from regional 
restricted brain regions (Autry and Monteggia 2012). It has been shown that baseline depression 
behaviour in the dentate gyrus sub-region of the hippocampus has not been altered, even if dentate 
gyrus expression of BDNF is required for antidepressant efficacy (Adachi, Autry et al. 2009). Of note, 
specific deletion in the ventral tegmental area (VTA) exerts an opposing effect, resulting in an 
antidepressant-like response (Berton, McClung et al. 2006; Krishnan, Han et al. 2007). With the 
background of stress towards BDNF and the susceptibility to develop depression-related behaviours, it 
is accepted that BDNF plays an important role. However, how loss of BDNF alters vulnerability to 
stress has not been under investigation (Advani, Koek et al. 2009; Autry, Adachi et al. 2009). Some 
studies, report that BDNF heterozygous mice show altered depression-related behaviour after acute or 
sub-chronic stress (Advani, Koek et al. 2009). Conditional or inducible BDNF mutants suggest that 
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depression behaviour in male mice from these lines is indistinguishable from that in control mice after 
chronic mild stress (Ibarguen-Vargas, Surget et al. 2009).  
A.4.1.2 Animal models related to stress 
After chronic social stress, BDNF deletion in the VTA reduces depression-related behaviour (Berton, 
McClung et al. 2006). These inconsistencies suggest differences in circuitry or BDNF/pro-BDNF 
functions (Autry and Monteggia 2012). An overview of recent, though inconsistent studies assessing 
stress paradigms and hippocampal BDNF expression in rodents is shown in Table 1.  
Similar to findings in human tissue, BDNF mRNA and protein expression are increased after long-
term antidepressant therapies, such as electroconvulsive therapy, and many drugs, including SSRIs, 
norepinephrine reuptake inhibitors, tricyclic antidepressants, and atypical compounds in corticolimbic 
brain areas, including the hippocampus in animal models (Nibuya, Morinobu et al. 1995; Altar, 
Whitehead et al. 2003; Balu, Hoshaw et al. 2008). Additionally, infusion of BDNF into the midbrain, 
ventricles, or regions of the hippocampus results in increased antidepressant-like behaviour 
(Shirayama, Chen et al. 2002; Hu and Russek 2008). These findings are supported by the 
overexpression of dominant-negative TrkB, which leads to loss of antidepressant efficacy, suggesting 
that TrkB activation is required for antidepressant behavioural effects (Saarelainen, Hendolin et al. 
2003).  
Table 1. Stress paradigms to mimic depression related behaviour in animal studies. The effects on BDNF 
expression are indicated with arrows to mark an increase or decrease. Though, it is accepted that BDNF plays an 
important role to develop stress-related behaviour in mice and rats, data from the literature are inconsistent, 
suggesting differences in circuitry of BDNF functions. [1] (Smith, Makino et al. 1995), [2] (Nibuya, Morinobu 
et al. 1995), [3] (Ueyama, Kawai et al. 1997), [4] (Rasmusson, Shi et al. 2002), [5] (Barrientos, Sprunger et al. 
2003), [6] (Pizarro, Lumley et al. 2004), [7] (Schulte-Herbruggen, Fuchs et al. 2009), [8] (Roceri, Hendriks et al. 
2002), [9] (Roceri, Cirulli et al. 2004), [10] (Xu, Luo et al. 2004), [11] (Murakami, Imbe et al. 2005), [12] 
(Bergstrom, Jayatissa et al. 2008). 
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A.4.2 BDNF in depressed patients 
To measure BDNF in human subjects, researchers use either blood or post-mortem brain samples. In 
post-mortem studies, reductions in the expression of pro-BDNF were also seen unilaterally in the 
hippocampus, but not in the DG, of subjects suffering from depression (Dunham, Deakin et al. 2009). 
The first investigations regarding the relation between BDNF and depression were cross-sectional 
studies like on the one hand simple assessment of current serum BDNF levels of treated and non-
treated depressed patients and healthy controls (Karege, Perret et al. 2002; Shimizu, Hashimoto et al. 
2003; Ziegenhorn, Schulte-Herbruggen et al. 2007). On the other hand, cohort studies assessed serum 
(Gervasoni, Aubry et al. 2005; Hellweg, Ziegenhorn et al. 2008; Okamoto, Yoshimura et al. 2008; 
Piccinni, Del Debbio et al. 2009) and plasma BDNF levels (Piccinni, Del Debbio et al. 2009) over 
time course before and after a defined antidepressant treatment. Further studies have been conducted 
as randomised controlled trial (RCT), the highest standard for clinical studies, to compare the 
influence of several antidepressant drugs on serum BDNF levels. (Ziegenhorn, Schulte-Herbruggen et 
al. 2007; Huang, Lee et al. 2008; Basterzi, Yazici et al. 2009; Gorgulu and Caliyurt 2009; Matrisciano, 
Bonaccorso et al. 2009). In the majority of clinical studies BDNF levels have been found lower in 
serum (Karege, Perret et al. 2002; Shimizu, Hashimoto et al. 2003; Huang, Lee et al. 2008; Sen, 
Duman et al. 2008; Gorgulu and Caliyurt 2009; Matrisciano, Bonaccorso et al. 2009) or plasma (Lee, 
Kim et al. 2007; Dreimuller, Schlicht et al. 2012) in depressed patients. In some cases these reductions 
are correlated with higher scores in specific depression evaluation scales (Gorgulu and Caliyurt 2009). 
Of note, not all studies show lower serum BDNF levels in depressed patients (Basterzi, Yazici et al. 
2009). Nonetheless, there are some exceptions with a few studies reporting no differences in plasma or 
serum BDNF levels between depressed patients and healthy controls (Fernandes, Gama et al. 2009; 
Gustafsson, Lira et al. 2009). Few studies also suggest a gender specificity regarding BDNF levels 
during depression (Huang, Lee et al. 2008; Ozan, Okur et al. 2010). Both, healthy and depressed males 
showed higher serum BDNF levels than female subjects (Ozan, Okur et al. 2010). Therefore, it is 
important to correct for possible confounders inter alia gender, age, time of blood withdrawal, 
smoking status and alcohol intake (Bus, Molendijk et al. 2011). Data regarding effects of 
antidepressants on systemic blood BDNF levels have been inconsistent too, even when related to 
identical chemical substance classes, like selective serotonin reuptake inhibitors (SSRIs) (Hellweg, 
Ziegenhorn et al. 2008; Matrisciano, Bonaccorso et al. 2009). Evidence from the literature seems to 
promote that a successful antidepressant therapy intervention is accompanied with a normalization of 
BDNF blood levels. However, recent studies do not show a general increase of BDNF levels restricted 
to antidepressant drugs (Hellweg, Ziegenhorn et al. 2008; Basterzi, Yazici et al. 2009; Matrisciano, 
Bonaccorso et al. 2009). A summing up of literature about BDNF blood levels in depressed patients is 
listed in Table 2. 
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Table 2. Recent studies investigating blood BDNF levels with regard to depression and therapy 
intervention. Inclusion criteria are connected to diagnosis of depression and therapy interventions. Either 
serum or plasma has been assessed and changes of BDNF involving an increase, decrease or no change of 
BDNF levels are indicated with arrows. If antidepressants are not described in detail different substances of 
antidepressant classes were administered. [1] (Karege, Perret et al. 2002), [2] + [3] (Shimizu, Hashimoto et al. 
2003), [4] (Gervasoni, Aubry et al. 2005), [5] (Aydemir, Deveci et al. 2005), [6] (Marano, Phatak et al. 2007), 
[7] (Yoshimura, Mitoma et al. 2007), [8] (Ziegenhorn, Schulte-Herbruggen et al. 2007), [9] + [10] (Hellweg, 
Ziegenhorn et al. 2008), [11] (Okamoto, Yoshimura et al. 2008), [12] (Gustafsson, Lira et al. 2009), [13] 
(Piccinni, Del Debbio et al. 2009), [14] (Basterzi, Yazici et al. 2009)], [15] (Matrisciano, Bonaccorso et al. 
2009), [16] (Gorgulu and Caliyurt 2009), [17] (Diniz, Teixeira et al. 2010), [18] (Tadic, Wagner et al. 2011), 
[19] (Wolkowitz, Wolf et al. 2011), [20] (Birkenhager, Geldermans et al. 2012) , [21] (Gedge, Beaudoin et al. 
2012), [22] (Dreimuller, Schlicht et al. 2012), [23] (Zhou, Xiong et al. 2013).  
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The underlying mechanism contributing to the augmentation of BDNF, upon antidepressant therapy 
are poorly studied in humans but might reflect changes in the brain. Nevertheless, one study (Cattaneo, 
Bocchio-Chiavetto et al. 2010) indicates that an increase of serum BDNF upon antidepressant 
treatment is associated with changes in BDNF mRNA levels in leukocytes, suggesting that these cells 
might play an active role in the mechanism of antidepressant action. Moreover, endurance training 
also induced an increase of BDNF levels in the hippocampus and enhanced release of BDNF from the 
human brain (Seifert, Brassard et al. 2010). This is in line with the thesis that physical exercise seems 
to have beneficial effects on depressed patients (Dimeo, Bauer et al. 2001; Pedersen, Pedersen et al. 
2009; Conn 2010). Furthermore, sleep deprivation, as adjuvant to antidepressant therapy, seems 
equally to be associated with increases in BDNF levels (Gorgulu and Caliyurt 2009; Piccinni, Del 
Debbio et al. 2009).  
A.4.3 BDNF polymorphisms in depression 
The research for variations at the Bdnf gene has resulted in the identification of several single 
nucleotide polymorphisms (SNP) but the rs6265 has been the mostly studied until now. This 
functional polymorphism is located at nucleotide position 196 of the human Bdnf gene and is 
characterized by the substitution of a guanine to adenine base, which generates the replacement of 
valine by methionine at codon 66 (Val66Met) in the amino acid sequence. The Val66Met 
polymorphism has been associated with abnormal intracellular trafficking and regulated secretion of 
BDNF in cultured hippocampal neurons (Egan, Kojima et al. 2003). Furthermore, there is evidence 
that human subjects carrying the Met allele reveal abnormal hippocampal activation (Egan, Kojima et 
al. 2003), as well as poorer episodic memory (Egan, Kojima et al. 2003) and verbal recognition 
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memory (Goldberg, Iudicello et al. 2008). Other studies have equally shown smaller hippocampal 
volumes compared to Val/Val homozygotes (Szeszko, Lipsky et al. 2005; Bueller, Aftab et al. 2006; 
Montag, Weber et al. 2009). Furthermore, researchers identified SNP variations in the Bdnf and 
NTRK2 (TrkB) genes that might be involved in antidepressant treatment outcome and that have been 
previously reported in this context (Hennings, Kohli et al. in press).  
Whether the presence of specific BDNF polymorphisms may predispose the individual to develop 
major depression is still under investigation (Yulug, Ozan et al. 2010). Of note, animal studies support 
the idea that the Val66Met polymorphism may serve as a genetic predictor of future development of 
depressive disorders (Chen, Jing et al. 2006; Chen, Bath et al. 2008). In humans this is supported by 
some studies indicating that Met66 allele carriers are more liable to have geriatric depression than do 
Val66 homozygote individuals (Hwang, Tsai et al. 2006; Taylor, Zuchner et al. 2007; Lin, Hong et al. 
2009). Of note, the literature reports that BDNF Val66Met polymorphism has been associated with 
major depression (Licinio, Dong et al. 2009), a risk for suicidal behaviour (Sarchiapone, Carli et al. 
2008; Schenkel, Segal et al. 2010) as well as with rumination in healthy adults (Beevers, Wells et al. 
2009), a behaviour characterized by the tendency to brood and repeatedly think about negative 
information, that is correlated with depression (Donaldson, Lam et al. 2007). Despite these findings, 
other studies did not find an obvious association of this BDNF variant with the disease itself (Chen, 
Lawlor et al. 2008; Liu, Xu et al. 2009; Verhagen, van der Meij et al. 2010), but there seems to be a 
relation of Val66Met polymorphism to the levels of BDNF. Both, patients and healthy controls 
carrying the Val66Met polymorphism have been exhibited lower BDNF serum levels than Val 
homozygote subjects, regardless of gender (Ozan, Okur et al. 2010). It has been suggested that genetic 
factors play a key role in both variation of response to treatment and incidence of adverse effects to 
medication (Schosser and Kasper 2009). It could be shown that rs7103411, Val66Met (rs6265) and 
rs7124442 BDNF polymorphisms are related with worse response to antidepressant treatment over 6 
weeks in major depression (Domschke, Lawford et al. 2010), particularly in the melancholic 
depression (for rs7103411 and Val66Met) and anxious depression (for rs7124442) clinical subtypes.  
In conclusion, there is some clinical evidence for an important effect of the genetic variability in 
BDNF on the risk to develop depressive behaviours and depression-associated mood disorders, such as 
suicide. Data indicate that the Val66Met polymorphism is associated with alterations in brain anatomy 
and memory performance, and that it might play a role on the individual response to antidepressant 
therapy.  
A.4.4 Neurotrophins in brain disorders with cognitive impairment 
Apart from their role in the pathophysiology of depression, neurotrophins seem to be implicated in 
other neuropsychiatric diseases as well, suggesting they might be a common pathogenic factor. 
Epidemiological and neurobiological evidences support a strong relationship between depression and 
dementia and several common pathophysiological mechanisms have been described, some of them 
involving neurotrophin signalling (Caraci, Copani et al. 2010). In the initial stage of Alzheimer`s 
  A. Introduction 
20 
disease (AD), for example, cognitive impairment is often accompanied by mood instability and 
depressive symptoms (Assal and Cummings 2002) and the prevalence of AD is higher in persons with 
a history of major depression (Kessing and Andersen 2004). Several evidences lead to the hypothesis 
that BDNF deficiency might be one of the bridges between AD and major depression (Tsai 2003). 
Indeed, beta-amyloid (Abeta) protein deposits, which are observed in AD patients, seem to be 
associated with changes in BDNF content in serum and in cortical regions. Analysis of BDNF content 
in the serum of patients at two different stages of AD dementia revealed that BDNF values are 
increased in early stages of AD, while they decrease with the course of the disease, correlating with 
the severity of dementia (Laske, Stransky et al. 2006). Transgenic mouse models of AD suggest that 
the decreased BDNF expression is dependent on the aggregation state of Abeta as well as on large 
Abeta oligomers (Peng, Garzon et al. 2009). Additional to the information available on the link 
between BDNF and AD, there is also evidence for changes in neurotrophin content occurring in the 
course of other neurodegenerative pathologies such as Parkinson`s disease, schizophrenia and bipolar 
disorder (Murer, Yan et al. 2001; Kapczinski, Frey et al. 2008; Manfredsson, Okun et al. 2009). By 
employing a multi analyte proteomics profiling in plasma samples from schizophrenic patients, it has 
been found that BDNF might be a candidate biological marker for schizophrenia (Domenici, Wille et 
al. 2010). However, there are studies which show no changes in plasma BDNF in schizophrenic 
patients compared to healthy controls (Shimizu, Hashimoto et al. 2003; Lee and Kim 2009) or 
decreased serum levels at the onset of the first episode (Chen da, Wang et al. 2009) and during relapse 
(Chen da, Wang et al. 2009). In sum, available data from the literature indicate that neurotrophins 
might be a link between depression and other neuropsychiatric disorders. This is particularly true for 
BDNF in the case of AD, whose co-prevalence with major depression is high. It has been proposed 
that therapeutic use of BDNF itself or of drugs targeting its production may constitute a valid 
alternative to treat depressed patients with cognitive impairment or AD concomitant with depression 
(Tsai 2003).  
A.5 Resilience and neuroadaptation 
The brain may be considered as a primary mediator and target of stress resiliency and vulnerability 
processes because it adapts to changing environments and regulates the behavioural and physiological 
responses to a given stressor. It constantly sorts relevant from irrelevant external inputs and engages 
body systems to respond to these changes. The concept of emotional or psychological resilience has 
been a keystone of psychiatric thinking in responses to trauma for many years (Rutter 1985).  
In the brain, corticosteroids play a key role in adaptive plasticity, as well as in the damage resulting 
from allostatic (physiological changes) overload (Sapolsky and Pulsinelli 1985; McLaughlin, 
Roozendaal et al. 2000). Modulators that work synergistically promote adaptation or damage, 
including the mineralcorticoid (MR) and glucocorticoid (GR) receptors, which bind the same hormone 
(cortisol in humans and corticosterone in rodents) in the brain, though with a difference in affinity. 
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Acting in concert with glucocorticoids, neurotrophins, such as BDNF, play an important role (Chen, 
Bath et al. 2008). Chronic stress can decrease BDNF expression in the brain (Smith, Makino et al. 
1995; Smith and Cizza 1996), via a complex relationship (Isgor, Kabbaj et al. 2004). The Bdnf gene is 
negatively regulated by activated corticoid receptors (Schaaf, Hoetelmans et al. 1997). As a result of 
BDNF polymorphisms or changes in BDNF levels, alterations in BDNF signalling can be considered 
as risk factor in the development of neuropsychiatric diseases (Bath and Lee 2006; Soliman, Glatt et 
al. 2010). On the other hand, compromised BDNF signalling may result in a lack of stress effect. 
BDNF haploinsufficient mice show shrunken dendrites in the CA3 region of the hippocampus when 
compared to wild type mice. These mice do not show further shrinkage of hippocampal dendrites 
when chronically stressed in contrast to wild type mice, which do show stress-induced shrinkage 
(Magarinos, Li et al. 2011). While such results may be explained by a floor effect, another possibility 
is that BDNF is a limiting factor in the ability of the brain to show plasticity (Horch, Kruttgen et al. 
1999; Horch and Katz 2002). Thus trophic factors such as BDNF are facilitators of plasticity, and the 
outcome may be negative (e.g. epilepsy) (Heinrich, Lahteinen et al. 2011) or positive (e.g. recovery 
from depression) (Castren 2005) depending on other factors operating at the time.  
It is accepted that depression, and associated cognitive impairment, may be a result of an inability to 
return to normal functioning following a stressful or distressing psychological or physical situation, 
and therefore may be an example of a reduction in the capacity for plasticity and/or lack of resilience 
(Karatsoreos and McEwen 2011). In a sense, brain circuits become somehow locked and only 
exogenous interventions may succeed in promoting recovery and ameliorating the behavioural effects 
(Karatsoreos and McEwen 2011). The shrinkage of brain areas occurring in prolonged depression and 
a lack of plasticity could be a failure of resilience. Treatments that increase brain plasticity can 
effectively mobilize a brain that has become stuck, improving the behavioural symptoms by treating 
an underlying problem of plasticity. However, enhancing brain plasticity for someone who is 
depressed and in a negative environment may lead to adverse outcomes, such as suicide (Castren and 
Rantamaki 2010). Moreover, BDNF may be a facilitator of negative plasticity, such as epilepsy 
(Kokaia, Ernfors et al. 1995; Scharfman 1997; Heinrich, Lahteinen et al. 2011).  
Researchers have examined the role that BDNF plays in susceptibility to developing stress-related 
mood disorders, but preclinical investigations have not yet demonstrated how loss of BDNF alters 
vulnerability to stress (Advani, Koek et al. 2009; Autry, Adachi et al. 2009). Differences in 
observations are likely to arise as a result of variations in the type of stressors, duration of stress, 
choice of behavioural assay or endpoint, mouse strain, and brain pathway examined.  
In the context of stress-related mood disorders, resilience refers to the capacity of an individual to 
avoid negative social, psychological and biological consequences that would otherwise compromise 
their psychological or physical well-being. Resilience in humans is reported to represent an active, 
adaptive process and not simply the absence of pathological responses (Charney 2004; Feder, Nestler 
et al. 2009). A principal mediator of the impact of stress on brain and behaviour is activation of the 
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HPA axis, which results in widespread hormonal, neurochemical and physiological alterations 
(Herman and Cullinan 1997). Glucocorticoids, released from the adrenal cortex as a consequence of 
HPA axis activation, interact with steroid receptors expressed throughout brain that function primarily 
as transcription factors to regulate cellular function beyond the time scale to acute stress effects. In 
detail, glucocorticoid receptors and mineralocorticoid receptors, which respond to glucocorticoids, are 
expressed at high levels in hippocampus, amygdala, PFC and other limbic and midbrain structures, 
where they modulate the neural circuitry and neuroendocrine systems that underlie behavioural 
responses to stress. The effects of stress on the HPA axis depend on the developmental timing of the 
stress, as well as other critical factors such as stress magnitude, type and duration (Russo, Murrough et 
al. 2012). Many stress-induced changes are adaptive, but some seem to be damaging. Impairment of 
normal HPA function to regulate and terminate stress responses can result in many forms of 
deregulation, as illustrated by sustained elevations of glucocorticoid levels, which further affect 
neuroendocrine systems including immune responses, metabolism, and reproduction.  
A.6 Sleep and BDNF 
Sleep is an important component of human homeostasis (Han, Kim et al. 2012). It is generally 
accepted that sleep disruption is associated with abnormal brain function. A recent study revealed a 
biological link between synaptic plasticity in the cerebral cortex and sleep homeostasis (Huber, Esser 
et al. 2007). A key follow-up study provided evidence that the degree of BDNF expression during 
wakefulness is causally linked to the extent of slow wave activity (SWA), a sensitive marker for sleep 
pressure and sleep need, in the subsequent rest period (Faraguna, Vyazovskiy et al. 2008). Since the 
body´s stress system plays a critical role in adapting to a continuously changing and challenging 
environment, it is an important question whether these systems are affected by sleep loss. As sleep is 
dependent on several neurotransmitter systems, it is not surprising that sleep complaints have been 
reported in more than 80% of patients with depression or schizophrenia and that sleep abnormalities 
are common in patients with Alzheimer´s or Parkinson´s disease (Wulff, Gatti et al. 2010). Sleep 
problems are common features in many stress-related mental disorders; problems that may lead to 
impairment of physical and mental health because sleep loss is often followed by higher stress 
vulnerability (Morin, Rodrigue et al. 2003). Activation of the HPA axis by infusion of CRH has been 
demonstrated to produce sleep disruption in normal individuals (Steiger 2002). Equally, disruption of 
sleep control has wide-spread effects on all aspects of neural and neuroendocrine function (Wulff, 
Gatti et al. 2010). These effects include impaired cognition, impaired emotions, metabolic 
abnormalities, reduced immunity and elevated risks of cancer and coronary heart disease (Wulff, Gatti 
et al. 2010). In general, in the beginning of sleep the activity of HPA axis is suppressed continually. In 
the latter part of sleep, the HPA secretory activity increases so it is close to the maximum circadian 
rhythm immediately after waking up. The prominent activity of the HPA axis and sympathetic nervous 
system influences the overall amount of rapid eye movement (REM) sleep (Vgontzas, Bixler et al. 
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2001). Therefore, the circadian regulation of stress hormones with the rise of ACTH and cortisol in the 
morning is the crucial control factor to regulate the end of sleep (Weibel, Follenius et al. 1995). The 
fact that beginning and end of sleep involve HPA axis activity and the close temporal relationship 
between the axis and sleep provides a clue to estimate the effects of stress on sleep (Han, Kim et al. 
2012). Additionally, the immune system is also influential in the relationship between stress and sleep 
via cytokines, which act as signalling molecules of the immune system such as interleukin-1 beta (IL-
1β), tumour necrosis factor (TNF), and interferon. Many cells in the body produce pro- and 
inflammatory cytokines, they regulate each other and are in turn, regulated by glucocorticoids and 
catecholamines (Sapolsky, Romero et al. 2000). It has been demonstrated that cytokine activities are 
under neuroendocrine control (Jankovic 1994) through light/dark secretion of the hormone melatonin 
(Maestroni, Conti et al. 1988). Significant circadian or diurnal variations have been demonstrated in 
serum cytokine and cytokine receptor expression profiles including IL-2, IL-10, IL-1β, IL-6, TNF-α, 
IFN-γ, and IFN receptors (Young, Matthews et al. 1995; Lundkvist, Robertson et al. 1998; Takane, 
Ohdo et al. 2002). Likewise, BDNF was shown to be subjected to diurnal variation, in men and mice 
(Bova, Micheli et al. 1998; Schaaf, Duurland et al. 2000; Begliuomini, Lenzi et al. 2008; Piccinni, 
Marazziti et al. 2008; Choi, Bhang et al. 2011; Hamatake, Miyazaki et al. 2011). Furthermore, a 
possible physiological co-regulation between plasma BDNF and cortisol levels was suggested 
(Begliuomini, Lenzi et al. 2008).  
Insomnia is a patient-reported problem, considered as sleep disorder as defined by the DSM-IV, 
regarding difficulties falling asleep or maintaining asleep, e.g. numerous awakenings, difficulty 
returning to sleep after awakenings, or awakening too early and struggle to return to sleep (Buysse 
2013). It affects up to one third of the general population and epidemiological and clinical studies have 
shown that a high number of insomnia subjects also suffer from a concomitant mood disorder mainly 
depression or an anxiety disorder (Buysse, Reynolds et al. 1994; Schramm, Hohagen et al. 1995; 
Breslau, Roth et al. 1996; Ohayon 1997; Ohayon, Caulet et al. 1997). Suffering from insomnia is 
reliably distinguishable from good sleep by self-reported sleep symptoms, such as sleep latency (time 
to fall asleep) or wakefulness after sleep onset of longer than 30 minutes (Lichstein, Durrence et al. 
2003). Insomnia disorders have been considered as primary and secondary (comorbid), depending on 
whether the sleep problem is triggered by another medical or mental disorder or medication/substance 
use (Buysse 2013). It has been shown that insomnia and psychiatric disorders interact in multiple 
ways, evidenced by the fact that only insomnia is infrequent (Ohayon and Roth 2003). Stress related 
insomnia is transient and persists for only few days. In the clinical setting a major problem is chronic 
insomnia, which is also called physiological insomnia (Han, Kim et al. 2012). Abnormalities in sleep 
timing and sleep architecture are recognized as common co-morbidities in numerous psychiatric 
disorders (Wulff, Gatti et al. 2010). These changes are usually described as difficulties in imitating and 
maintaining sleep during the night. Of note, persistent insomnia increases the risk of relapse into a new 
major depressive disorder episode (Pigeon, Hegel et al. 2008). Interestingly, some of the tricyclic (e.g. 
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amitriptyline, imipramine, clomipramine) and non-tricyclic antidepressants (e.g. mirtazapine, 
trazodone) have very pronounced sedative effects, and are commonly used as hypnotic agents in 
individuals without depression (Wulff, Gatti et al. 2010). Therefore, part of the efficacy of some 
antidepressants can be attributed to their direct action on sleep. Until know, the causal link between 
insomnia and psychopathology is not fully understood. 
Moreover, sleep deprivation (SD) plays a distinct role in antidepressant therapy intervention. 
Nevertheless, the therapeutic effect is uncertain and only transient for one or a few days (Giedke and 
Schwarzler 2002). Standard treatment is total sleep deprivation (TSD) where the patient stays awake 
for one whole night and the following day. During these 40 hours of continuous wakefulness the 
patient abstains from any napping (Giedke and Schwarzler 2002).A variant of TSD is partial sleep 
deprivations (PSD) (Schilgen and Tolle 1980). Generally, PSD is chosen for treatment intervention 
since a total deprivation of sleep for one night is extremely exhausting for the patient and is combined 
with huge effort of personnel requirements. In PSD, patients got to bed as usual and are woken up at 
1.30am and remain awake till the next evening (approximately 20h of continuous wakefulness). 
Another possibility is to deprive the patients of sleep in the early morning hours, staying awake until 
1.30am, then sleeping until 7.00, because at this time the circadian course of several body functions 
changes direction (Schilgen and Tolle 1980). 
Human studies investigating the association of BDNF with sleep disorders, especially insomnia, are 
missing and results from animal studies are inconsistent (Cirelli and Tononi 2000; Sei, Saitoh et al. 
2000; Guzman-Marin, Ying et al. 2006). Until now, there was only one study measuring serum and 
plasma BDNF levels in sleep apnoea patients – representing a very specific subgroup of sleep 
disturbance –, which were found to be similar between patients and controls (Staats, Stoll et al. 2005).  
  
  B. Manuscripts 
25 
B. Manuscripts  
B.1 BDNF: an indicator for insomnia? 
M Giese
1
, E. Unternährer
2,3
, H Hüttig
2
, J Beck
4
, S Brand
4
, P Calabrese
2
, E Holsboer-Trachsler
4
 and A 
Eckert
1 
 
1
Neurobiology Laboratory for Brain Aging and Mental Health, Psychiatric University Clinics, University of 
Basel, Basel, Switzerland; 
2
Division of Cognitive Psychology and Methodology, Department of Psychology, 
University of Basel, Basel, Switzerland; 
3
Division of Clinical Psychology and Epidemiology, Department of 
Psychology, University of Basel, Basel, Switzerland and 
4
Center for Affective, Stress and Sleep Disorders, 
Psychiatric Hospital of the University of Basel, Basel, Switzerland E-mail: Anne.Eckert@upkbs.ch 
 
Molecular Psychiatry advance online publication, 12 February 2013; doi:10.1038/mp.2013.10 
 
 
In the last decade, brain-derived neurotrophic factor (BDNF) has become increasingly accepted as a 
central mediator of the effects of stress on neuronal plasticity and its implication for psychopathology. 
Neurotrophic functions of BDNF are implicated with neuronal survival, learning, memory, appetite 
and sleep.
1,2
 The neurotrophin hypothesis is based on these features and proposes that stress-related 
mental disorders result from stress-induced decreases in BDNF expression.
3
 Sleep problems are 
common features in many stress-related mental disorders, problems that may lead to impairment of 
physical and mental health because sleep loss is often followed by higher stress vulnerability.
4
 Thus, 
insomnia is very common among depressed patients.
5
 Of note, in accordance with the „neurotrophin 
hypothesis of depression‟, BDNF seems to be involved in major depression and antidepressant 
action.
6,7
 Although a majority of studies have concentrated on specifying the role of BDNF in 
depression, the relation between BDNF and insomnia has not been a focus of recent research. Here we 
investigated serum BDNF levels of adults with current symptoms of insomnia and non-sleep disturbed 
controls. The study was approved by the local ethics committee of the University of Basel. The sample 
pool consisted of 50 adults (mean±s.d. age=54.66±11.63 years), including patients with a previous 
diagnosis of restless legs syndrome (RLS) or periodic limb movement (PLM) but without other 
neurological symptoms, and age-matched controls. The eligibility criterion for sleep-disturbed 
participants was to suffer from at least sub-threshold insomnia (n=26, including 19 patients previously 
diagnosed with RLS/PLM and 7 controls); participants qualified as sleep-healthy subjects (n=24, 
including 7 patients with previous RLS diagnosis and 17 controls) by scoring below the cut-off (sum 
score of 8) for sub-threshold insomnia according to the Insomnia Severity Index, which is based on the 
DSM-IV diagnostic criteria for insomnia. Consistent with previous work,
8
 there was a significant 
difference in serum BDNF levels between smokers and non-smokers (t(47)=3.066; P=0.004, ns: age, 
BMI and sex). Therefore, smoking was included as a covariate in subsequent analyses. Of note, 
participants suffering from current symptoms of insomnia (n=26) exhibited significantly decreased 
serum BDNF levels compared with sleep-healthy controls (n=24; F(1)=5.017; P=0.03; Figure 1a). In 
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addition, serum BDNF levels were significantly correlated with severity of insomnia in all participants 
(n=50; rp=-0.409; P=0.004; Figure 1). There were no differences in serum BDNF levels between 
participants on medication (RLS 
medications included pramipexol 
and ropinirol, hypnotics, 
antidepressants, antipsychotics 
and others) and those without such 
drugs. Furthermore, serum BDNF 
levels did not differ between those 
with previous RLS/PLM diagnosis 
(n=26, including 19 patients with 
and 7 patients without insomnia 
symptoms) and those without such 
diagnoses (n=24, including 17 
controls without and 7 with 
insomnia symptoms), which 
supports the view that serum 
BDNF levels are associated with 
sleep independently of diagnosis. 
We found subjective sleep 
impairment to be associated with 
lower serum BDNF levels, 
whereas reported good sleep was 
related to higher serum BDNF 
levels, as shown for those 
suffering from current insomnia 
compared with sleep-healthy 
subjects. To confirm the relevance of our preliminary findings, we investigated an additional 
independent control sample of adults (n=12, male non-smokers) that had recovered from occupational 
burnout and after 12 weeks of aerobic exercise training. To assess insomnia, we used the sleep-related 
items of the Beck Depression Inventory. Again, serum BDNF levels were significantly lower in those 
reporting symptoms of fatigue (n=6) compared with sleep-healthy subjects (n=6; t=2.2625; P=0.025; 
Figure 1b) and were significantly correlated (n=12, rp=-0.639; P=0.025) with the symptoms of 
tiredness and fatigue known to reflect malfunction of sleep as the prime cause of impairments in daily 
life. The results from these two different samples are not strictly comparable, given the different 
methods of assessing disturbed sleep wake regulation as insomnia and day time fatigue, but despite or 
perhaps because of this, we believe that these findings support the hypothesis of an increased stress 
 
Figure 1. Correlation between serum brain-derived neurotrophic 
factor (BDNF) levels and insomnia severity index ratings. Analysis 
showed a significant correlation of BDNF levels with severity of 
insomnia across the sample as a whole (rp=-0.409; P=0.004). Black 
circles represent smokers (r=-0.331; P=0.21) and open circles 
represent non-smokers (r=-0.511; P=0.002). (a) Plotted estimated 
means by ANOVA ± s.e.m. of serum BDNF levels controlled for 
smoking of sleep-disturbed (n=26; 15.41±1.77 ng ml
-1
) and sleep-
helathy (n=24; 21.15±1.80 ng ml
-1
) subjects. (b) Means ± s.e.m. of 
serum BDNF levels of tired and fatigued (n=6; 9.86±2.16 ng ml
-1
) 
and sleep-healthy (n=6; 26.08±2.30 ng ml
-1
) subjects. * Denotes 
statistical significance at P<0.05. 
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vulnerability due to sleep loss, which may lead to decreased BDNF secretion. Such a decrease might 
be associated with a decrease in BDNF mRNA expression in peripheral blood mononuclear cells 
and/or may correspond to a decline of BDNF concentration in the brain. To what extent peripheral 
BDNF levels correspond to brain BDNF levels remains unknown. However, the use of serum BDNF 
concentration as potential indicator of brain alteration is justified by extensive evidence.
9
 Although we 
report a reduction of BDNF levels linked to sleep disturbance, others have consistently shown that 
prolonged wakefulness as a result of sleep deprivation, which can be considered as a stressor for the 
brain, leads to an increase in BDNF.
10
 Using a bidirectional stress model as an explanatory approach, 
we hypothesise that chronic stress induces a deregulation of the HPA system, leading in the long term 
to sleep disturbance and decreased BDNF levels, whereas acute sleep deprivation, for example, one 
night of sleep deprivation, can be used as therapeutic intervention in some insomniac or depressed 
patients as a compensatory process to normalize BDNF levels. BDNF has also been considered as a 
predictor of therapeutic response in major depression. However, very recent data indicate that the 
increase in serum levels of BDNF during antidepressant treatment appears to be confined to some but 
not all antidepressants and does not coincide with amelioration of clinical symptoms.
6
 On the basis of 
our results, this discrepancy might stem from changes in central BDNF concentrations, following 
reduced insomnia rather than depressive symptoms and antidepressants differentially influencing 
sleep. Thus, our preliminary findings suggest that serum BDNF levels are not associated with a 
specific (categorical) diagnosis, but may be associated with insomnia symptoms independent of 
diagnosis (dimensional). In line with this, we suggest that, when analysing serum BDNF levels in 
depressed patients, insomnia symptoms should be carefully controlled, as well as improvements in 
sleep during therapy. Further studies with a larger number of patients and a design including objective 
measurements of sleep, such as sleep polysomnography, should be conducted to verify the results of 
our exploratory investigation and to elucidate the underlying mechanisms more closely, especially the 
role of the stress hormone system. 
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ABSTRACT 
Background: Sleep plays a pivotal role in normal biological functions. Sleep loss results in higher 
stress vulnerability and is often found in mental disorders. There is evidence that brain-derived 
neurotrophic factor (BDNF) could be a central player in this relationship. Recently, we could 
demonstrate that subjects suffering from current symptoms of insomnia exhibited significantly 
decreased serum BDNF levels compared with sleep-healthy controls. 
Objective: In accordance with the paradigm indicating a link between sleep and BDNF, we wanted to 
investigate if the stress system influences the association between sleep and BDNF. 
Method: Participants with current symptoms of insomnia plus a former diagnosis of Restless Legs 
Syndrome (RLS) and/or Periodic Limp Movement (PLM) and sleep healthy controls were included in 
the study. Participants completed questionnaires on sleep (ISI, Insomnia Severity Index) and stress 
(PSS, Perceived Stress Scale) and provided a blood sample for determination of serum BDNF levels. 
Results: We found a significant interaction between stress and insomnia with an impact on serum 
BDNF levels. Moreover, insomnia severity groups and score on the PSS each revealed a significant 
main effect on serum BDNF levels. Insomnia severity was associated with increased stress experience 
affecting serum BDNF levels. Of note, the association between stress and BDNF was only observed in 
subjects without insomnia. Using a mediation model, sleep was revealed as a mediator of the 
association between stress experience and serum BDNF levels.  
Conclusions: This is the first study to show that the interplay between stress and sleep impacts BDNF 
levels suggesting an important role of this relationship in the pathology of stress-associated mental 
disorders. It is already known that stress is a major effector of BDNF regulation. Hence, we suggest 
sleep as key mediator at the connection between stress and BDNF. If sleep is maintained or disturbed 
  B. Manuscripts 
30 
might explain why some individuals are able to handle a certain stress load while others develop a 
mental disorder.  
 
INTRODUCTION  
Sleep is associated with physical and mental health. [1,2,3,4]. Sleep loss impairs various 
endocrine, physiological [5] as well as neuronal functions [6,7,8] and is often followed by higher 
stress vulnerability, reduced environmental adaptation and cognitive impairment [9]. Moreover, 
insomnia is often observed in many stress-related disorders [3]. Evidence indicates that BDNF 
could play a role in this association: i) in animal studies BDNF levels decreased after chronic 
stress [10,11,12,13], ii) serum BDNF levels decreased in stress-related major depressive disorder 
[14,15,16], iii) BDNF plays a role in sleep homeostasis [17,18,19]. Additionally, a recent study by 
our group showed that insomnia is associated with decreased serum BDNF levels [20]. 
The major stress response system, the hypothalamic–pituitary–adrenal (HPA) axis, facilitates the 
adaptation to stress. Chronic stress can lead to a deregulation in this biological stress system 
[21,22,23], which was suggested to influence BDNF levels in limbic brain structures in animal 
studies and in blood from the human periphery, namely serum and plasma [10,11,12,14,15,16]. In 
rodents it was shown that acute and chronic stress decreased levels of BDNF in the dentate gyrus 
and the hippocampus. This reduction seemed to be mediated partly via stress-induced 
glucocorticoids [24]. 
Next to the nervous system, BDNF is found in the periphery of humans and other mammals 
[25,26]. Since the protein can cross the blood brain-barrier in both directions, circulating BDNF 
correlates with cortical BDNF concentrations [27]. In addition to the classic functions of BDNF as 
neurotrophin, several studies involving human subjects and animal models provide preliminary 
data supporting a role for BDNF in stress and mood disorders [14,28,29,30,31]. 
Altogether, these findings suggest a possible role of the interplay between stress, sleep and BDNF 
however the relation remains unclear. Therefore the aim of this study was to test how stress and 
sleep could affect serum BDNF levels. To elicit our hypothesis, participants with current 
symptoms of insomnia and non-sleep disturbed controls were asked to complete questionnaires on 
insomnia and stress experience. In the same sample, we could already demonstrate an association 
between decreased serum BDNF levels and insomnia severity [20]. 
 
MATERIALS AND METHOD  
Participants and Procedure 
Participants were recruited in three different ways. First, patients with a former diagnosis of Restless 
Legs Syndrome (RLS) and or Periodic Limb Movement (PLM) were recruited from the Department of 
Sleep and Depression Research of the Psychiatric University Clinic Basel, Switzerland. Second, we 
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Table 1. Descriptive characteristics of study participants. A 
total sample size of N=50 were included in the analyses. 
Descriptive data are presented in means (M) and standard 
deviations (SD). Absolute numbers of participants are given (N) 
and expressed as percentage (%). 
 
 
Abbreviations: means (M), standard deviation (SD), brain-
derived neurotrophic factor (BDNF), Insomnia Severity Index 
(ISI), Perceived Stress Scale (PSS), restless legs syndrome 
(RLS), periodic limb movement (PLM) 
recruited participants using a study participant database provided by the Institute of Psychology of the 
University of Basel and third – in order to reach older participants – we asked members of an 
organization of the elderly to participate. 
At first contact, the study was explained by phone, e-mail or face-to-face. When interested in 
participation, patients and controls were thoroughly informed about the study and received an 
information-package containing detailed study information and several questionnaires, which they 
were asked to complete at home. Participants were then invited to a personal appointment in the 
facilities of the Department of Sleep and Depression Research of the Psychiatric University Clinic 
Basel in Switzerland, where they were requested to arrive fasting in the morning at 7.45 a.m. to 
provide a blood sample and complete several questionnaires. The local ethics committee of Basel 
approved the study protocol. All participants gave written informed consent in accordance with 
the declaration of Helsinki and 
received financial compensation. A 
total of 50 participants were included 
in the study (for further details see 
Table 1 – characteristics of study 
participants). Besides a 
sociodemographic questionnaire to 
assess sex, age and BMI, participants 
also had to indicate substance 
consumption (coffee, cigarettes, 
alcohol, marihuana and other illegal 
drugs) and pharmaceutical intake, 
which could interfere with the 
biological analyses [32,33,34,35]. 
Marihuana and illegal drugs were 
ignored in further analyses, as no 
participant indicated to consumption 
any of these two. Only smoking was associated with serum BDNF levels and therefore included in 
subsequent analyses. 
 
BDNF analysis 
For serum sampling, blood was obtained in a serum separator tube from the antecubital vein between 
7.45 and 8.00a.m. After 30 minutes of clotting time, the whole blood was centrifuged at 1000xg for 
30min to separate and collect the serum. Aliquots were kept at -80°C until assaying. 
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Serum BDNF levels (concentration: ng/ml) were assessed with an enzyme-linked 
immunoabsorbant assay (ELISA) kit (Promega BDNF Emax®, Madison, Wis.). Samples were 
appropriately diluted (between 1:100-1:150) and detection of total soluble BDNF was carried out 
in an antibody sandwich format like described in the manufacturers protocol. The absorbance was 
measured within 30 minutes in a microplate reader at 450nm to determine BDNF concentrations 
according to the standard curve. All assays were carried out in duplicates and means were 
calculated. 
 
Questionnaires 
SLEEP Participants completed the Insomnia Severity Index (ISI) [36], which is an established 
screening questionnaire for insomnia. The ISI is a 7-item scale that yields a quantitative index of 
insomnia severity and is partly based on the DSM-IV diagnostic criteria for insomnia [19]. 
Participants were asked to specify on a 5-point Likert scale ranging from 0 (= not at all) to 4 (= very 
much) to what extend they suffered from difficulties in falling asleep or maintaining sleep and early 
awakenings during the last two weeks. Additionally they are asked to rate satisfaction with sleep, 
daytime sleepiness and worrying about (bad) sleep. A sum score of 8 to 14 indicates that the 
respondent suffers from sub-threshold insomnia. A score of 15 and higher indicates clinical insomnia. 
STRESS Stress perception was assessed using the German versions of the Perceived Stress Scale 
(PSS) [19], which consists of 10-items and is used to determine perceived overall stress occurring 
in the previous month. The German version of the PSS has satisfactory internal consistency and 
test-retest reliability [14]. Answers were given on a 5-point Likert scale ranging from 1 (= never) 
to 5 (= very often), with higher scores reflecting greater perceived stress. 
 
Statistical Analysis  
For descriptive purposes means and standard deviations and errors respectively were calculated for 
stress, sleep and serum BDNF levels and potential confounding variables.  
First, potential confounders were examined and later included in the analyses if they were significantly 
correlated with scores on the ISI, PSS or serum BDNF levels (Pearson‟s (r) or Spearman‟s (rs) 
correlation coefficients). Second, we performed an ANCOVA to assess the main effects of sleep and 
stress and their interaction with regard to serum BDNF levels. Third, we conducted mediator models 
(see figure 3) using the bootstrap calculation of an SPSS macro according to Preacher and Hayes [37]. 
All analyses were performed using SPSS Statistics 20 for Macintosh. A p-value smaller than 0.05 was 
considered as significant. 
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Figure 1. Serum BDNF levels and stress experience in subjects suffering from current insomnia. (A) Mean 
serum BDNF levels of the insomnia severity groups. Plotted means and standard errors estimated by ANCOVA 
with serum BDNF as dependent variable, insomnia severity group as independent variable and smoking as 
covariate. For all three insomnia severity groups the overall effect on serum BDNF was not significant 
(F(2)=2.67; p=0.080). Contrasts showed that serum BDNF levels in the group with no insomnia were 
significantly higher compared to the groups reporting sub-threshold and clinical insomnia (F(1)=5.33; p= 
0.026); (no insomnia n=24; sub-threshold insomnia n=16, clinical insomnia n=10). (B) Correlation between 
insomnia severity score, indicated by the Insomnia Severity Index (ISI), and stress perception, indicated by the 
Perceived Stress Scale (PSS). Analysis showed a significant correlation between scores on the ISI and the PSS 
across the whole sample (r=0.548; p<0.001). * Denotes statistical significance at p<0.05 
RESULTS  
Participant characteristics and potential confounders 
Descriptive characteristics of participants are shown in Table 1. There was a significant association of 
BDNF with smoking (rp = 0.408, p = 0.004) which was included as a covariate in further analyses. To 
assess the influence of insomnia severity we divided all participants into three subgroups according to 
their score on the Insomnia Severity Index: subjects with no insomnia (score 0-7, n = 24), sub-
threshold insomnia (score 8-14, n = 16) and clinical insomnia (score 15-30, n = 10). Serum BDNF 
levels did not differ between diagnosis groups (RLS, PLM, sleep-healthy) and were not influenced by 
medication [20]. 
 
Serum BDNF levels, sleep and stress  
Previously, we could show that an increase in severity of insomnia was associated with a decrease in 
serum BDNF levels of the same sample [20]. Serum BDNF levels in the group with no insomnia were 
significantly higher compared to the groups reporting sub-threshold and clinical insomnia (Figure 1a). 
As expected, stress experience on the PSS increased with rising sum score of insomnia severity 
(rp=0.548; p<0.001) (Figure 1b).  
To obtain a better understanding of the complex interplay between stress, insomnia and BDNF we 
calculated an ANCOVA (BDNF as dependent variable, insomnia and stress as independent variables 
and smoking as covariable). We found a significant interaction between stress and insomnia with an 
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impact on serum BDNF levels (F=6.180, p=0.017). Moreover we found a significant main effect for 
the independent variables: (i) insomnia severity groups (F=7.775, p=0.008) with an incremental 
decrease in serum BDNF levels from the no insomnia to the sub-threshold and to the clinical insomnia 
group, (ii) score on the PSS (F=8.230, p=0.006), with decreased serum BDNF levels associated with 
increased scores on the PSS and (iii) the covariate smoking (F=14.154, p<0.001). Of note, an 
association between the PSS and BDNF was only observed in subjects with no insomnia (rp=-0.511, 
p=0.013) compared to subjects with sub-threshold (rp=0.069, p=0.814) or clinical insomnia (rp=0.199, 
p=0.608) (Figure 2). 
To further elucidate a mutual relationship between the three parameters stress, sleep and BDNF we 
calculated a mediation model as described by Preacher & Hayes [37]. In the first model (Figure 3a) we 
defined stress as mediator of the relationship between sleep and BDNF. Results showed a significant 
„a‟ path (t=4.36; p<0.001) between sleep and stress. The „b‟ path between stress and BDNF was not 
significant (t=-0.92); p=0.365). The „c‟ path between sleep and BDNF was significant after inclusion 
of stress as mediator (t=-2.05; p= 0.046). The indirect „ab‟ path was not significant (bootstrap 95% 
confidence intervals: lower =-0.385, upper =0.169, p>0.05). In the second model (Figure 3b) we 
defined sleep as mediator of the relationship between stress and BDNF. As expected, the „a‟ path 
(t=4.36; p<0.001) between stress and sleep was significant. Here, also the „b‟ path between sleep and 
BDNF was significant (t=-2.05; p=0.046). The „c‟ path between stress and BDNF was not significant 
when the mediator sleep was included (t=-0.92; p=0.365) and this time the indirect „ab‟ path was 
significant (bootstrap 95% confidence intervals: lower =-0.522, upper =-0.046; p<0.05). Both models 
               
Figure 2. Correlation between serum BDNF levels and scores on the Perceived Stress Scale (PSS) by 
insomnia severity group according to the Insomnia Severity Index (ISI). Analyses showed a significant 
correlation (partial correlation controlled for smoking) between BDNF and stress only in subjects with no 
insomnia (rp=-0.511, p=0.013) compared to subjects with sub-threshold (rp=0.069, p=0.814) or clinical insomnia 
(rp=0.199, p=0.608). White squares represent subjects with no insomnia, black circles represent subjects with 
sub-threshold and black triangles represent subjects with clinical insomnia. 
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can explain 27.3% of the variation (adjusted R square) in the serum BDNF levels (F(7, 45)=7.013; 
p<0.001). 
DISCUSSION 
The aim of this study was to investigate if the influence of the association between stress and sleep has 
an impact on serum BDNF levels. As previously shown, insomnia was correlated with decreased 
serum BDNF levels [20]. In the present study we found an interaction between stress and insomnia 
which affects serum BDNF levels. Interestingly, an association between stress and BDNF was only 
found in subjects without insomnia. Therefore the present results are in line with the assumption that 
stress somehow affects the link between sleep and BDNF.  
To further elucidate this finding we investigated two mediator models (Figure 3a and b). In the first 
model, stress was defined as mediator of the relationship between sleep and BDNF and in the second 
model sleep was determined as the mediator of the relationship between stress and BDNF. The first 
model did not identify stress as a mediator of the relationship between sleep and BDNF. Notably, our 
second model revealed that sleep mediated the association between stress and BDNF. Importantly, this 
means that increased stress negatively affects sleep and in turn decreases BDNF levels. Our main 
finding is partly in line with previous research showing a major role for stress on BDNF regulation. 
Our results suggest for the first time sleep as a key mediator in the connection between stress and 
BDNF.  
The results of our study revealed that only subjects who suffer from increased stress and at the same 
time from comorbid sleep disturbances show decreased BDNF levels. We argue that stressed while not 
 
Figure 3. Mediation models for the interplay between stress, sleep and BDNF. (A) Stress as a mediator in 
the relationship between sleep and BDNF. Analyses revealed a significant „a‟ path (t=4.36; p<0.001) between 
sleep and stress. The „b‟ path between stress and BDNF was not significant (t=-0.92; p=0.365). The „c‟ path 
between sleep and BDNF was significant after inclusion of stress as mediator (t=-2.05; p=0.046). The indirect 
„ab‟ path was not significant (bootstrap 95% confidence intervals: lower =-0.385, upper =0.169, p>0.05). (B) 
Sleep as mediator in the relationship between stress and BDNF. The „a‟ path between stress and sleep was 
significant (t=4.36; p<0.001), as was the „b‟ path between sleep and BDNF (t=-2.05; p=0.046). The „c‟ path 
between stress and BDNF was not significant when the mediator sleep was included (t=-0.92; p= 0.365). In this 
model the indirect „ab‟ path was significant (bootstrap 95% confidence intervals: lower =-0.522, upper =-0.046; 
p<0.05). Both models explain 27.3% of the variation (adjusted R square) in serum BDNF levels (F(7.45)=7.013; 
p<0.001). Smoking was included as covariate in both models. * Denotes statistical significance at p<0.05 and 
*** p<0.001 
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sleep-disturbed subjects have BDNF levels similar to non-stressed subjects. This highlights the 
importance of good sleep in dealing with stress. We assume that the interplay between decreased 
BDNF, chronic sleep impairment and increased stress levels is an essential mechanism in the 
pathology of stress-associated mental disorders. If sleep is maintained or disturbed might explain why 
some individuals are able to handle a certain stress load while others develop a mental disorder. 
Thereby, adequate levels of BDNF could promote neuronal plasticity, a factor supporting mental 
health. 
Our study is the first to combine two predictors, sleep and stress, regarding BDNF levels. Moreover, 
we were able to bring sleep and stress in relation to each other. This is important since stress-related 
mood disorders are characterized by multifactorial features and are often comorbid with sleep 
disorders. Another strength is that we did not simply compare patients and controls by diagnosis but 
investigated insomnia severity in all subjects. Therefore we are able to make statements about the 
consequences of insomnia in general rather than related to a specific clinical diagnosis. This is 
important with regard to underlying mechanisms independent of a diagnosis. In sleep healthy subjects 
we saw a strong association between stress and serum BDNF levels. This could indicate that in these 
subjects stress results in decreased BDNF levels, while this association was diminished in sleep-
disturbed subjects. A reasonable argument could be that chronic sleep loss, probably caused by stress, 
is associated with reduced circulating serum BDNF in general, as well as an impaired stress adaptation 
system. 
This study has also some limitations. First, there could be various other biological factors influencing 
BDNF levels, which were not analysed in this study such as physical activity [38] alterations in 
neurotransmitter and hormone production and function, cytokines, [39]as well as genetic and 
epigenetic mechanisms [40,41]. Second, further studies should examine other biological correlates of 
sleep impairment, difficulties in stress coping and elevated stress perception. Third, studies on patients 
with specific sleep-related disorders or with experimentally induced sleep restriction have to be 
conducted to generalize these results. Therefore, we suggest that future studies should investigate – 
next to subjective psychological stress ratings – objective endocrine stress parameters, such as cortisol 
and a greater sample sizes should be aspired. Fourth, there might be additional cofactors that were not 
assessed, such as comorbidly existing somatic and psychiatric disorders or nutritional intake.  
 
CONCLUSIONS 
This is the first study to show that stress experience and subjective sleep perception interact with each 
other and affect BDNF levels. We suggest that this interplay is involved in the pathology of stress-
associated mental disorders. We add new weight to our previous suggestion [20] to seriously consider 
the assessment of sleep when analysing BDNF as a marker in stress-related mood disorders, since 
several studies have found decreased levels of serum BDNF in various stress-related mental disorders, 
such as depression [14,42], posttraumatic stress disorder [43] and burnout syndrome [44], all of which 
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are associated with sleep-related problems. The underlying biological mechanisms e.g. involvement of 
the stress hormone system, have to be elucidated in future studies. 
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ABSTRACT 
Background: Brain-derived neurotrophic factor (BDNF) is an important member of the neurotrophin 
family of growth factors, abundant in the brain and periphery. Researchers have reported that serum 
BDNF levels in depressed patients are lower than those of healthy controls and the majority of studies 
reported increases of BDNF levels after antidepressant treatment (antidepressant pharmacotherapy, 
electroconvulsive therapy). Sleep deprivation (SD) and also partial sleep deprivation (PSD) are 
effective for patients with antidepressant medication-resistant depression. However, the underlying 
molecular mechanisms of SD is not well understood especially those explaining the rapid, but 
transient, antidepressant effect of SD.  
Methods: Twenty-eight patients suffering from MDD, which were naïve to sleep deprivation therapy, 
participated in this study. Participants experienced PSD with a supplementary mono-therapy of 
mirtazapine. In addition, the stimulant modafinil or placebo was applied starting during PSD. PSD-
response was assessed by 6 items of the Hamilton Depression Rating Scale (HDRS) before (day 0), 
during and after PSD (day 1) and at follow-up after two weeks (FU2). For serum sampling blood was 
obtained at seven different time points: at 8am (t1), 2pm (t2) and 8pm (t3) for baseline (day 0), at 
1.30am (t4) during PSD, as well as 8am (t5), 2pm (t6) and 8pm (t7) after PSD (day 1). 
Results: Notably, responders showed a significant diurnal BDNF serum variation the day before PSD, 
relative to non-responders. Similarly, responders showed a diurnal BDNF serum profile also after PSD 
in contrast to non-responders. PSD induced a fast increase in BDNF serum levels, descriptively, 
within a time frame of several hours at the day after PSD which parallels clinical findings. 
Accordingly, BDNF serum levels increased with decreasing depression scores in all participants. 
Adjuvant modafinil medication was not related to changes in BDNF serum levels. 
Conclusions: Our results indicate that the elasticity in diurnal serum BDNF variation is associated 
with favourable treatment response to PSD in patients suffering from MDD. Therefore, a normalized 
BDNF serum profile which oscillates in a circadian fashion seemed to precede, rather than follow a 
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favourable treatment outcome in depressed patients. Thus, we suggest that diurnal profiling of BDNF 
should be monitored at baseline especially before therapeutic intervention starts for the purpose of 
early response prediction.  
 
INTRODUCTION 
There is growing evidence that both the pathophysiology and the treatment of major depressive 
disorder (MDD) are linked to alterations of neurotrophic factor expression such as brain-derived 
neurotrophic factor (BDNF) in various brain regions, including the hippocampus [1,2,3]. These can 
involve reversible changes, which explain the link between depressive episodes and subsequent 
recovery with neuronal plasticity. Exposure to stress, which is related with, but not required for the 
onset of MDD [4] in humans, advances or worsens depressive episodes [5]. Preclinical and clinical 
studies demonstrate that reductions of the total volume of neurons and neuronal loss occur in stress 
and depression in the adult hippocampus [6]. These hippocampal alterations can be reversed by 
chronic antidepressant treatment [6].  
The stress response leads to an increase in glucocorticoids via activation of the hypothalamic–
pituitary–adrenal (HPA) axis. However, under chronic stress the HPA axis regulation may become 
deregulated. Such HPA axis alterations during an acute depressive episode and its normalization after 
successful treatment are the most consistently observed laboratory findings in patients with MDD 
[7,8,9]. In rodents it could be already shown that acute and chronic stress decreased levels of BDNF 
expression in the dentate gyrus and the hippocampus. This reduction seems to be mediated partly via 
stress-induced glucocorticoids [10].  
BDNF has received much attention among candidate downstream effectors involved in antidepressant-
mediated hippocampal neurogenesis [11]. Indeed, chronic antidepressant treatment seemed to be 
associated with an increased BDNF expression in the hippocampus [2]; likewise, a direct infusion of 
BDNF into the hippocampus was sufficient to produce an antidepressant-like action in mouse models 
of depression [12]. Taken together, multiple neurobiological mechanisms seem to be involved in 
mediating the therapeutic effects of antidepressant therapy. Some of these mechanisms seem to play a 
role for neuroprotection and neurogenesis. The complexity of these mechanisms could explain the fact 
of slow onset of action in antidepressant treatments [13,14,15].  
Neurotrophic functions of BDNF are connected to neuronal survival, memory, learning, appetite and 
sleep [16,17], leading to the neurotrophin hypothesis which is based on these features and claims that 
stress-related mental disorders result from stress-induced decreases in BDNF expression [18]. In sum 
the “neurotrophic hypothesis of depression” proposes that depression is associated with reduced brain 
BDNF levels and that successful antidepressant treatment is mediated by an increase in BDNF levels 
[18,19]. However, revealing the cellular and molecular pathways underlying the action of 
antidepressants remains an extremely challenging mission. 
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Circulating BDNF is found in both human serum and plasma and a large amount is stored in human 
platelets [20]. However, the source of peripheral BDNF is not clear yet. Since the protein can cross the 
blood brain-barrier in both directions, circulating BDNF correspondingly correlates with cortical 
BDNF concentrations [21] suggesting peripheral BDNF as a promising candidate biomarker in the 
association with depression and antidepressant treatment response. Several studies showed that serum 
BDNF levels in drug-free MDD patients were significantly lower compared to healthy subjects 
[22,23,24,25]. Other studies reported that plasma BDNF levels were lower in drug-free MDD patients 
[24,26]. Some clinical studies have evaluated the changes of plasma or serum BDNF levels before and 
after antidepressant treatments among MDD patients and most studies reported increases of BDNF 
levels after antidepressant treatment [22,27,28,29,30], although very recent data indicate that the 
increase in serum levels of BDNF during antidepressant treatment appears to be confined to some but 
not all antidepressants [31]. Moreover, some studies provide important evidence that an 
antidepressant-induced increase in BDNF levels is more prominent in responders than non-responders 
[28,32] or even exclusively restricted to responders [32]. 
Furthermore, different antidepressant strategies including antidepressant drugs, electroconvulsive 
therapy (ECT) and physical exercise were associated with an increase of peripheral BDNF levels 
[33,34]. Sleep deprivation (SD) is clinically well documented, robust, and fast-acting method for the 
treatment of severely depressed patients [35]. Beside SD of the total night, partial sleep deprivation 
(PSD) in the second half of the night has also shown comparable antidepressant effects in patients with 
major depression [35]. However, the underlying molecular and cellular mechanisms of SD are not well 
understood, especially those explaining the rapid, although transient, antidepressant effect of SD, since 
a relapse into depression occurs in most patients following the recovery night [36]. Recent evidence 
indicates that an up-regulation of Bdnf gene expression after SD in rats might be relevant for its mode 
of action [33,37]. Moreover, evidence also supports a role for BDNF in the modulation and mediation 
of circadian rhythms which seem to be disturbed in mood disorders. Interestingly, the presence of a 
diurnal BDNF rhythm was also recently demonstrated in healthy humans where plasma BDNF 
displayed highest concentrations in the morning, followed by a substantial decrease throughout the 
day, and the lowest values at midnight [38]. However, diurnal variation of blood BDNF was neglected 
until now in studies investigating MDD patients. 
In the present study, we wanted firstly to explore the effect of partial sleep deprivation (PSD) as an 
alternative antidepressant intervention on serum BDNF levels within an acute time window of 12 
hours during day after PSD night in MDD patients. Secondly, we investigated whether treatment with 
modafinil, which seems to be able to reduce micro sleep during SD thereby stabilizing the treatment 
response to PSD when compared with placebo [36], has an impact on serum BDNF levels after PSD. 
Due to the fact that BNDF levels oscillate in the periphery in a circadian fashion, we thirdly studied 
diurnal variation of serum BDNF levels before and after PSD and whether serum BDNF profile is 
altered in response to PSD. Finally, we wanted to investigate whether baseline BDNF levels before 
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PSD and treatment-associated changes are related to clinical and depressive symptoms and/or 
treatment response. Thus, this study was specifically designed to gain for the first time results on daily 
peripheral BDNF profiles in MDD patients and to explore the hypothesis if a diurnal BDNF pattern is 
associated with prediction of antidepressant therapy response already at a very early stage of 
intervention, in this case within hours. This is in contrast to all other published studies where treatment 
related BDNF changes were collected and analysed not earlier than after one up to six weeks of 
antidepressive therapy. 
 
MATERIAL AND METHODS 
Subjects and study design 
Twenty-eight in- and out-patients (13 men, 15 women, age 45.1 ± 12.1 years; range 19–65 years) with 
the diagnosis of major depression (DSM-IV and ICD-10) participated in this study as previously 
published by Beck et al., 2010 [36]. For study design details, inclusion and exclusion criteria see Beck 
et al., 2010 [36]. In brief, all participants were naïve to sleep deprivation therapy and randomly 
assigned to either additional modafinil or placebo treatment. Inclusion criteria comprised a HDRS-
score of ≥15 and the presence of significant daytime sleepiness. PSD-response was assessed by 6 
items of the Hamilton Depression Rating Scale covering the items depressive mood, feelings of guilt, 
working and leisure activities, depressive inhibition, psychological symptoms of anxiety, somatic 
symptoms [39]. An improvement of at least 30% from baseline was required to determine PSD 
response. The modafinil group consisted of eight men and six women, age 46.2 ± 12.2 years (n=14, 
HDRS 21 item before PSD 21.71 ± 6.56 and at day after PSD 15.71 ± 9.12; 6 item before PSD 9.43 ± 
2.79 and at day after PSD 6.50 ± 3.69) and the placebo group of five men and nine women, age 43.9 ± 
12.2 years (n=14, HDRS 21 item before PSD 21.79 ± 4.72 and at day after PSD 12.64 ± 8.38; 6 item 
before PSD 8.71 ± 2.40 and at day after PSD 5.07 ± 3.85; values of all ratings were not different 
compared to modafinil) [36]. According to ethical considerations, all patients were treated with a 
monotherapy of 30mg mirtazapine daily at 9pm throughout the study (Figure 1). 
               
Figure 1. Study design and serum sampling. Blood was drawn at day 0 (baseline) before PSD at 8am (t1), 
2pm (t2), 8pm (t3) and at day 1 at 1.30am (t4), 8am (t5), 2pm (t6) and 8pm (t7). Placebo controlled additional 
morning treatment with the stimulant modafinil started during PSD and maintained over 14 days. Depression 
severity using the Hamilton Depression Rating Scale (HDRS) together with mood, tiredness and relaxation 
were assessed with Visual Analogue Scales (VASs) for psychological functioning at days 0, 1 and 2 (“after 
recovery night”) as well as after two weeks (day 14, FU2) of on-going treatment. 
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Compared to placebo, modafinil was efficient in reducing daytime microsleep following partial sleep 
deprivation but did not enhance the antidepressive effects of PSD and did not stabilize antidepressive 
effects over two weeks [35]. 
 
Serum sampling 
For serum sampling blood was obtained in a serum separator tube from the antecubital vein at seven 
different time points. Day 0 (before PSD) at 8am (t1), 2pm (t2) and 8pm (t3) for baseline and day 1 at 
1.30am (t4) during PSD, 8am (t5), 2pm (t6) and 8pm (t7) after PSD (Figure 1). After 30min of clotting 
time, whole blood was centrifuged at 1000xg for 30min to separate the serum. Serum was collected in 
aliquots to avoid several freezing cycles and kept at -80°C before assaying. 
 
Measurement of serum BDNF levels 
Serum BDNF levels were assessed with an enzyme-linked immunoabsorbant assay (ELISA) kit 
(Promega BDNF Emax®, Madison, Wis., United States). Samples were appropriately diluted 
(between 1:100-1:150) and detection of total soluble BDNF was carried out in an antibody sandwich 
format like described in the manufacturers protocol. The absorbance was measured within 30min in a 
microplate reader set at 450nm to determine BDNF concentrations according to the standard curve. All 
assays were carried out in duplicates and means were calculated. 
 
Behavioural ratings 
Severity of depression was evaluated by the 21 Item version of Hamilton Depression Rating Scale 
(HDRS; Hamilton, 1967) at day 0 before, day 1 after PSD, following the recovery night at day 2 and 
after 2 weeks (FU2). PSD-response was assessed by 6 items of the HDRS covering the items 
depressive mood, feelings of guilt, working and leisure activities, depressive inhibition, psychological 
symptoms of anxiety and somatic symptoms [39]. An improvement of at least 30% from baseline was 
required to determine PSD response according to [40].  
In addition participants were asked to rate their experienced level of relaxation at day 2 after recovery 
night on a Visual Analogue Scale (VAS) consisting of a horizontal line, 100mm in length, ranging 
from „not at all relaxed‟‟ at the left end to ,,extremely relaxed‟‟ at the right end. Participants marked on 
the line the point that represents their perception of the current state. The VAS score could range from 
0 to 10 and was determined by measuring in centimetres (with millimetre accuracy) the distance from 
the left hand end of the line to the point that the participant marked. 
 
Questionnaires to assess potential confounders 
Besides a sociodemographic questionnaire to assess sex, age and BMI, participants had to indicate 
substance consumption, which could interfere with biological analyses. 
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Statistical Analysis 
Analysis of variance (ANOVA) was used for multiple group parametric comparisons. Associations 
between variables were computed with Pearson`s correlations. To compare the effect size Cohen`s d 
was calculated to compare serum BDNF values among subjects, responders and non-responders. The 
level of significance was set at p ≤ 0.05. Preliminary calculations revealed that BDNF serum levels 
were not associated with sex and age (rs< .20xx, p > .35). Moreover, BDNF serum levels did not 
statistically significantly differ between smokers and non-smokers (all ts<1.56, p>0.13). As a result, 
sex, age and smoking were not entered as co-variates. 
 
RESULTS 
Daily serum BDNF profile from MDD patients before and after PSD 
At baseline (day 0), a diurnal variation pattern could be detected in serum BDNF levels from all 
participants (n=28) which decreased during the day starting with the highest concentration in the 
morning until BDNF concentrations reached lowest level in the night before PSD (Figure 2A). After 
PSD, descriptively though not statistically, BDNF levels were increased of 10.4% (at 8am), 16.2% (at 
2pm) and 12.3% (at 8pm) respectively, relative to the corresponding BDNF levels of day 0 (Figure 
2B). 
No effect of additional treatment with modafinil on BDNF levels 
To evaluate the effect of additional modafnil treatment starting at 1.30am during PSD we compared 
serum BDNF levels of day 1 between patients with modafinil and placebo treatment. A series of Chi-
square tests revealed no statistically significant associations between treatment condition and response 
           
Figure 2. Daily variation of serum BDNF levels. (A) Baseline serum BDNF levels (means ± SEM) decreased 
during the day starting with the highest concentration in the morning (8am, t1) until they reached lowest level 
after midnight (1.30am, t4) in all patients. (B) After PSD serum BDNF levels (means ± SEM) were elevated 
throughout day 1, relative to levels at baseline (day 0) of 10.4% at 8am, 16.2% at 2pm and 12.3% at 8pm. This 
difference in BDNF levels between baseline and day 1 was not statistically significant, but rather describes a 
trend of serum BDNF levels to increase after PSD.  
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Figure 3. Baseline changes of serum BDNF levels. 
BDNF levels (means ± SEM) were significantly 
elevated in patients who respond to PSD at day 1 
relative to non-responders at 8am, t1 (t=3.370, 
p=0.003). Effect size calculations indicated that higher 
BDNF levels were prominent in day 1 responders at 
8am, t1 (d=1.57), 2pm, t2 (d=0.78) and 8pm, t3 
(d=0.57) at baseline. ANOVA calculation revealed a 
significant group effect between responders and non-
responders at day 1 for baseline serum BDNF levels 
before PSD (F(1.87)=13.88; p=0.003).  
(response day 1: Χ2(1, N=25)=0.24, p=0.62; response day 2: Χ2(1, N=25)=0.05, p=0.82; response FU1 
Χ2(1, N=25)=0.27, p=0.87; response FU2: Χ2(1, N=24)=1.34, p=0.27). 
 
Treatment response and daily changes in serum BDNf levels 
BDNF and acute improvement on HDRS-6 
To assess whether this diurnal BDNF pattern was associated with an antidepressant treatment response 
to PSD we focused primarily on serum BDNF levels of day 0 before PSD with corresponding 
depression severity ratings after the intervention. Depressive patients who showed an acute 
improvement on the HDRS-6 after PSD on day 1 compared to day 0 exhibited a prominent diurnal 
pattern of serum BDNF levels at baseline (during the day 0 before sleep deprivation) (Figure 3). 
Serum BDNF levels were significantly 
elevated in responders (identified as acute 
responders on day 1) relative to non-responders 
at 8am (Figure 3) of both days (BDNF values 
at 8am: day 0, t=3.370, p=0.003; day 1, 
t=2.356, p=0.028; data not shown). In addition, 
acute responders at day 1 had descriptively 
higher BDNF levels at 2pm and 8pm at 
baseline (day 0: t2 and t3). Moreover, effect 
size calculations revealed that higher BDNF 
levels were prominent in acute responders 
relative to non-responders at 8am (t1) (d=1.57), 
2pm (t2) (d=0.78), 8pm (t3) (d=0.57) of day 0 
(Figure 3). Of note, there was no diurnal 
pattern of serum BDNF observable before the 
intervention in patients identified as acute non-
responders on day 1, which is reflected by a 
significant group effect between BDNF values 
of acute responders and non-responders at day 0 before PSD (F(1.87)=13.88; p=0.003).  
After recovery night, responders at day 2 (identified as responders on day 2) revealed descriptively 
higher BDNF levels relative to non-responders (data not shown). Effect size calculations emphasized 
increased BDNF levels in responders compared to non-responders at 8am (t1) (d=0.76), 2pm (t2) 
(d=0.67) at day 0 and 2pm (t6) (d=0.53) of day 1. 
 
BDNF and long-term improvement on HDRS-6 
In a further step we explored to which extent pre- and post-PSD serum BDNF levels of day 0 and 1 
exhibited diurnal pattern characteristics for long-term responders and non-responders (long-term 
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HDRS-6 ratings after two weeks [FU2]) (Figure 4A). Again, BDNF-levels at baseline were 
descriptively higher in long-term responders at 8am (day0, t1) compared to non-responders. Effect size 
calculations emphasized higher BDNF levels in FU2-responders at 8am (t1) (d=0.91), 2pm (t2) 
(d=0.71) of day 0, relative to non-responders (Figure 4A).  
In addition, there was a prominent daily change of serum BDNF after PSD in long-term responders. 
Thus, FU2 responders showed significantly higher serum BDNF levels after PSD on day 1 at 8am (t5) 
(t=2.993, p=0.007) and 2pm (t6) (t=2.846, p=0.010) compared to non-responders (Figure 4B). 
Furthermore, effect size calculations emphasized higher BDNF levels in FU2-responders at 8am (t5) 
(d=1.54) and 2pm (t6) (d=1.37) of day 1, relative to non-responders.  
Importantly, there was again no diurnal baseline BDNF pattern observable for patients specified as 
non-responders after 2 weeks (Figure 4A). However, after PSD at day 1 a trend to a slight diurnal 
BDNF change was recognizable (Figure 4B), which was clearly less pronounced compared to 
responders. 
 
Relationship between HDRS-6 improvement and treatment-related serum BDNF levels 
After PSD, descriptively though not statistically, BDNF levels were increased in responders of 8.2% 
(at 8am), 17.5% (at 2pm) and 20.8% (at 8pm) as well as in non-responders of 15.2% (at 8am), 21.2% 
(at 2pm) and 8.2% (at 8pm) respectively, relative to the corresponding BDNF levels of day 0 (Figure 
4B compared to 4A). The overall increase of serum BDNF on day 1 after PSD was prominent in 
responders as well as in non-responders at 2pm (Figure 4A, B). In agreement with other findings using 
different antidepressive treatment approaches [41,42], the HDRS-6 improvement 2 weeks after PSD 
              
Figure 4. Baseline and day 1 changes of serum BDNF levels. (A) BDNF levels (means ± SEM) were 
descriptively higher in patients who responded after 14 days of on-going treatment relative to non-responders at 
baseline. Effect size calculations indicated that higher BDNF levels were prominent in day 14 responders at 
8am, t1 (d=0.91) and 2pm, t2 (d=0.71). (B) There was a prominent increase in serum BDNF after PSD in day 14 
responders. Serum BDNF levels were significantly elevated at day 1 for 8am, t5 (t=2.993, p=0.007) and 2pm, t6 
(t=2.846, p=0.010) compared to non-responders.  
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was significantly correlated with an increase of serum BDNF levels in all patients (rp=-0.462; 
p=0.018) (Figure 5). 
Relationship between psychological functioning and treatment-related serum BDNF levels 
To assess whether psychological functioning in general is linked with post-PSD BDNF serum levels 
we correlated VAS scores for relaxation and mood after recovery night from day 2 with BDNF peak 
levels of day 1 at 2pm. The Visual Analogue Scale (VAS) has a long history of use for the assessment 
of subjective mood, strain, and pain, and the validity and reliability of this method is generally 
accepted. Here we found a significant correlation between increased relaxation (rp=-0.425, p= 0.03) or 
improved mood (rp=0.510, p=0.008) and increased BDNF levels in all patients (Figure 6A, B). 
 
                                        
Figure 5. HDRS-6 improvement and peak serum BDNF levels at day 1. Lower HDRS-6 response scores at 
day 14 (FU2), indicating an improvement of depressive symptoms, significantly correlated with an increase in 
serum BDNF levels at day 1, 2pm (t6) in all patients (rp=-0.462; p=0.018).  
            
Figure 6. Psychological functioning is linked to peak serum BDNF levels at day 1. (A) Higher serum BDNF 
levels from day 1 at 2pm (t6) after PSD significantly correlated with increased relaxation expressed as lower 
VAS score values after the recovery night on day 2 (rp=-0.425; p=0.03) in all patients. (B) Furthermore, after 
recovery night at day 2, improvement in mood expressed as higher VAS score values  significantly correlated 
with higher serum BDNF levels from day 1 at 2pm (t6) after PSD (rp=0.510; p=0.008) in all patients. (VAS) – 
Visual Analogue Scale 
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DISCUSSION 
Key findings of the present study indicate that BDNF serum levels exhibited a significant diurnal 
variation among responders when compared to non-responders in a sample of patients suffering from 
major depressive disorder (MDD). Subjects identified as acute responders after partial sleep 
deprivation (PSD) at day 1 and even after 2 weeks of follow-up were associated with a daily change of 
serum BDNF at baseline before PSD. This variation of peripheral BDNF abundance revealed 
characteristics of a diurnal pattern since levels decreased during the day starting with the highest 
concentration in the morning, whereas non-responders did not exhibit diurnal BDNF variation in their 
serum. Thus, we can conclude that the presence of a diurnal serum BDNF profile in MDD patients 
predicts therapy response. Of note, there are only few data available on diurnal variation of blood 
BDNF levels in healthy subjects, but nothing is known from MDD patients in this regard.  
Most biological functions are expressed in an oscillating manner within a 24-hour circadian period, 
regulated by endogenous biological clocks. A growing body of evidence also supports a role for 
BDNF and TrkB in the modulation and mediation of circadian rhythms. As a starting point, high levels 
of BDNF and TrkB expression were demonstrated in the rat suprachiasmatic nucleus (SCN) and 
hippocampus [43]. It was reported that BDNF protein and mRNA levels in the rat SCN showed 
evident signs of variation over the course of a circadian cycle. The SCN content of BDNF protein 
remained low throughout the subjective day, began to rise early in the subjective night, and reached 
peak levels near the middle of the subjective night [44]. Diurnal variation in BDNF protein expression 
levels was demonstrated in the cerebellum, hippocampus, and cerebral cortex [43,45]. Moreover, 
recognition that circadian rhythm disruption also plays a key role in mood disorders has led to the 
development of the new antidepressant agomelatine. Recent data from various groups showed that 
agomelatine led to an increase in BDNF expression in treated animals, and that this effect follows a 
specific temporal profile [46]. Interestingly, the presence of a diurnal BDNF rhythm was also recently 
demonstrated in healthy humans (only males were included in the study) where plasma BDNF 
displayed highest concentrations in the morning (8am), followed by a substantial decrease throughout 
the day, and the lowest values at midnight [38]. A similar circadian fluctuation in plasma BDNF levels 
was also found in women [47], even if the amplitude of the variation in BDNF levels appeared to be 
influenced by ovarian function with a blunted diurnal rhythm in the luteal phase. In the present study, 
we could confirm parallel changes in diurnal variation in serum BDNF in patients identified as 
responders of both gender. Thus, all the findings together emphasize the importance of the presence of 
a circadian BDNF rhythm in human health and wellbeing, while the absence seems to have a negative 
impact on successful treatment outcome in MDD. 
The decline in peripheral BDNF levels during the day may be ascribed to a circadian secretory model 
on the one hand. Thus, it can be speculated that BDNF is secreted with a pulsatory circadian rhythm 
that is characterized by a progressive reduction in the amplitude of pulses throughout the day. On the 
other hand, it has been shown that brain BDNF is able to cross the blood–brain barrier via a rapidly 
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saturable transport system [48]. While brain BDNF peaks around midnight and thus may exert its 
modulating effect on neuroplasticity and long-term potentiation [44], peripheral BDNF in the blood, 
namely, both of plasma and serum, peaks in the morning at 8am and exhibits its lowest expression 
level at midnight, indicating that BDNF cycles in opposite phases in brain and blood. Why there is a 
discrepancy in temporal expression profiles between blood and brain is not clear, but might be due to a 
rapid transition from brain to blood with a time delay of about 12 hours or might reflect the 
endogenous circadian rhythm of BDNF in the periphery which oscillates in anti-phase to that of the 
brain. Importantly, this repeatedly reproduced result is in line with findings of Sartorius and 
colleagues, which investigated correlations and differences between serum and brain tissue BDNF 
levels after ECT in rats [49]. They demonstrated a positive correlation between brain and serum 
BDNF concentrations providing evidence that it can be justified to measure serum BDNF levels but 
only by consideration of a time delay to monitor brain tissue alterations in the periphery. 
Ultimately, it is not clear to which extend diurnal changes of blood BDNF are related to a circadian 
secretory model or sex hormones next to malfunctions in the hypothalamic-pituitary-adrenal (HPA) 
axis regulation, different activity during the day and other environmental factors.  
Moreover, the present study demonstrated that diurnal BDNF serum variations were not changed by 
the adjuvant medication with modafinil as a stimulant during PSD, which is consistent with our 
previous finding showing that modafinil was not able to enhance the antidepressive effects of PSD and 
did not stabilize antidepressive effects over two weeks in these patients [36]. In addition, PSD itself 
had also no significant impact on diurnal serum BDNF profile. This further emphasizes the importance 
of the presence of a daily BDNF profile in a circadian fashion at baseline with regard to therapy 
response prediction and is in line with data from Wolkowitz and colleagues [50] who also found that 
serum BDNF levels (only measured at the single time point 10am) before treatment with SSRI 
(escitalopram or sertraline) predicted SSRI response in depressed patients and responders to treatment 
exhibited higher pre-treatment BDNF levels than did non-responders. Thus, one can speculate that 
diurnal BNDF variation represents a prerequisite for successful therapy response independent from the 
specific treatment strategy, e.g. antidepressants drugs or SD. 
Furthermore, our findings demonstrated that post-PSD BDNF serum levels were higher in acute 
(HDRS-6 ratings at day 1) as well as long-term (HDRS-6 ratings after two weeks) responders to 
treatment (≥ 30% improvement in depression ratings) when compared to non-responders. Consistently, 
increased BDNF serum levels (peak levels at 2pm at day 1) were associated with decreased depressive 
symptoms in all patients. These data are in line with other studies also providing evidence that an 
antidepressant-induced increase in BDNF levels is more prominent in responders than non-responders 
[42] or even exclusively restricted to responders [32], while the early non-increase in serum BDNF 
levels predicted failure of antidepressant treatment (different classes of antidepressants) in patients 
with major depression [51]. Notably, beyond the association of increased BNDF with decreased 
depressive symptoms, our results indicate an improved emotional state of mind and greater relaxation 
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related to elevated serum BDNF levels further confirming a normalizing effect on the deregulated 
relationship between BDNF, stress and HPA axis system in MDD.  
In the present study, post-treatment BDNF levels were investigated already at an very early stage of 
intervention, in this case within hours after PSD (up to 18 hours by using a six hour interval post PSD, 
namely at 8am, 2pm, and 8pm). This is in contrast to all other published studies where treatment 
related BDNF changes were collected and analysed not earlier than after one up to six weeks of 
antidepressive therapy. The rapid effect of PSD on BDNF levels, however, might be related to the 
rapid antidepressant effect of PSD at day 1 and a relapse into depression occurs in most patients 
following the recovery night (already at day 2) [36]. In agreement with our findings, others have 
consistently shown that prolonged wakefulness as a result of sleep deprivation, which can be 
considered as a stressor for the brain, leads to an increase in BDNF [33], while sleep disturbance was 
linked to reduction of BDNF levels [52], confirming a bidirectional stress model with which both can 
be explained, chronic stress induces a deregulation of the HPA system leading in the long term to 
sleep disturbance and decreased BDNF levels, whereas acute sleep deprivation, e.g. PSD, can be used 
as therapeutic intervention in some insomniac or depressed patients as a compensatory process to 
normalize BDNF levels.  
In summary, the present study adds very important new evidence to the currently existing BDNF 
literature dealing with MDD: i) an a-priori diurnal BDNF serum level variation precedes a more 
favourable treatment outcome in depressive patients, and ii) PSD may exert a very rapid effect on 
serum BDNF levels within a time frame of several hours at the day after PSD which parallels clinical 
findings.  
Thus, we suggest that next to analyses of pre- and post-treatment serum BDNF levels collected at a 
single time point per day, diurnal proof of peripheral BDNF should be monitored at baseline especially 
before intervention starts for the purpose of therapy response prediction. Moreover, the results of our 
study might provide a valuable model for the investigation of biomarkers in the treatment of MDD and 
other psychiatric disorders and might encourage research in the area of early predictors of therapy 
response in order to shorten the duration of psychopharmacological treatment until the determination 
of insufficient effectiveness. Further studies with a larger number of patients and different treatment 
strategies should be conducted to verify the results of our exploratory investigation and to elucidate 
the underlying mechanisms more closely, especially the role of the stress hormone system. 
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C. Discussion 
Stress-related mood disorders like major depressive disorder (MDD) are complex, multivariate and 
imply numerous neuronal substrates and brain regions. Currently available antidepressants acutely 
increase monoamine levels but the chronic treatment is required for the onset of antidepressant effect, 
meaning that enhanced serotonergic and/or noradrenergic neurotransmission is not the only main 
trigger factor for clinical actions of these drugs. 
In the three present studies we investigated serum BDNF levels in the context of stress-related 
disorders, especially MDD. In recent decades, BDNF became more and more a key molecule in the 
field of biomarkers and/or target research for treatment of mood disorders, since there is increasing 
evidence suggesting a role in the pathophysiology of mood disorders (Shimizu, Hashimoto et al. 
2003). Of note, BDNF alone may not be sufficient to explain the pathology of stress-related mood 
disorders, but it remains an important risk factor for the development. Furthermore, stress-related 
disorders are often accompanied with sleep related problems and sleep is an important component of 
physical and mental health (Van Dongen and Dinges 2003; Stein, Belik et al. 2008; Walker 2009). 
Therefore, our research focussed also on disturbed sleep wake regulation, namely insomnia, besides 
MDD. Of note, our results showed that serum BDNF levels significantly correlated with severity of 
insomnia and that sleep-disturbed subjects revealed reduced serum BDNF levels (Giese, Unternahrer 
et al. 2013) in the setting of this explorative study. The significance of our preliminary data was 
further emphasized when we assessed an external control group that had recovered form occupational 
burnout. Again, serum BDNF levels were significantly lower in those subjects reporting symptoms of 
fatigue compared to sleep healthy subjects. This was in line with a significant negative correlation of 
serum BDNF levels with symptoms of tiredness and fatigue. These findings strongly support the 
hypothesis of increased stress vulnerability due to sleep loss, in conjunction with decreased serum 
BDNF levels. This could be explained from two points of view. First, decreased serum BDNF levels 
could reflect impaired BDNF concentrations in the CNS, which contribute to hippocampal atrophy, 
like it is repeatedly documented for MDD (Stockmeier, Mahajan et al. 2004). Since the hippocampus 
provides an important source of negative modulation of the HPA stress hormone axis through its 
projection to the hypothalamus, hippocampal dysfunction could contribute to the deregulation of the 
stress response system, which ends up in higher stress vulnerability. Secondly, it is known that 
perturbed sleep behaviour is common in many stress-related disorders. Our results revealed that sleep 
behaviour is linked to BDNF (Giese, Unternahrer et al. 2013) and therefore sleep may be a key 
moderator for stress perception. Meaning that, impaired sleep wake regulation could affect the stress 
response system, leading to a malfunction of the negative feedback regulation of the HPA system and 
increased stress vulnerability. Therefore, increased glucocorticoid levels may act on BDNF expression 
(Smith, Makino et al. 1995; Schaaf, de Jong et al. 1998) via the transcription factor CREB and supress 
BDNF expression, namely BDNF mRNA. In animal models related to stress (Russo-Neustadt, Ha et 
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al. 2001) it has already been shown that BDNF mRNA levels were significantly decreased. However, 
the link between stress and sleep is missing. Nevertheless, both approaches are in line with a possible 
explanation that parallel BDNF changes occur in the brain and serum of depressive patients (Shimizu, 
Hashimoto et al. 2003). It was already reported that brain and serum BDNF levels underwent similar 
changes during maturation and aging processes in rats (Karege, Schwald et al. 2002) and that serum 
and cortical BDNF levels are positively correlated (Karege, Schwald et al. 2002). Still, a major 
question, which is not solved yet, is whether low BDNF levels are primary or secondary in stress-
related disorders. Primary reduced BDNF levels might reflect a genetic vulnerability and secondary 
reduced BDNF levels might explain the hypothesis of an acquired biological vulnerability. From the 
perspective of stress-induced BDNF reduction, like discussed above, decreased BDNF levels may 
reflect a collapse of the stress-adaptation system and its failure to protect the brain from stress-induced 
neuronal degeneration. A possible link in this open question might be sleep, acting as a moderator 
between stress perception and adaptation of BDNF. So far there are no studies, which investigated the 
interplay of stress, sleep and BDNF.  
Therefore, we hypothesized a possible effect of stress on the previously identified relationship of sleep 
and BDNF levels in a further study. Our results show that the severity of sleep impairment is 
positively correlated with stress experience. Interestingly, this is only found in subjects without 
insomnia, which highlights the importance of sleep and sleep quality in terms of stress load and 
perception. If sleep is maintained or disturbed might explain why some individuals are able to handle a 
certain stress load while others develop a mental disorder. Indeed, we identified that sleep mediates the 
association between stress and sleep (manuscript submitted), which could explain that increased stress 
negatively affects sleep and in turn affects BDNF levels. Therefore, our results extend the finding of 
stress-induced BDNF decrease with the suggestion of sleep as a possible key mediator. It is likely that 
the interplay of chronic sleep impairment and in turn increased stress levels, reflected by decreased 
BDNF levels, is an essential mechanism in the pathology of stress-associated mood disorders. 
This would be in line with the idea that not only the balance of certain neurotransmitter, namely 
monoamines, is crucial to develop a mood disorder, but also adequate BDNF levels (Castren 2005) 
promoting neuronal plasticity, which provides a factor supporting mental health. Of course, there 
might be additional factors influencing mental health with regard to BDNF and the stress response 
system. However, BDNF seems to play an important role in the activity-dependent information 
processing of the brain and the body, rather than just the balance of distinct signalling molecules. Next 
to appropriate neuronal communication restricted by BDNF levels reflecting a healthy range, we could 
show in a further study that not only single endpoint levels per se at a certain time point during the day 
but rather a daily variation profile shed light on the adaptive process regarding BDNF. Notably, we 
could show that the diurnal variation profile of serum BDNF is an important factor regarding 
prediction of antidepressant therapy response. Moreover, our results showed that the antidepressant 
therapy intervention of the present study, namely partial sleep deprivation (PSD) (manuscript 
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submitted), is followed by a fast increase of serum BDNF levels within hours. This is in contrast to 
most studies assessing BDNF with regard to antidepressant therapy response after four to six weeks, 
while overall BDNF levels increased within 24 hours between 10-16 % already after PSD in the 
present study. However, most importantly, subjects who were identified as responders directly after 
PSD night, revealed a prominent diurnal variation of serum BDNF levels during baseline day before 
spending half of the night awake. This finding was also true for responders after 14 days, but could not 
be shown for non-responders, which exhibited a more or less flat line of serum BDNF levels 
throughout the baseline day. Furthermore, at the day after sleep deprivation, the diurnal variation of 
BDNF was even more prominent reflected by increased levels per daily time point and a distinctive 
diurnal curve. In addition, increased BDNF levels after PSD were associated with improvement of 
depressive symptoms in MDD patients. Hence, our results support the hypothesis that a diurnal 
variation throughout the day seems to be important for therapy response at least for the therapy 
intervention settings in the present study. But this could explain additionally, like discussed above, 
why people react differently regarding to certain stressors. Sleep deprivation for one or half of the 
night as an antidepressant therapy intervention represents an acute stressor for body and brain. As 
compensatory response BDNF increases to normalize disturbed serum BDNF levels. Interestingly, this 
prolonged wakefulness was only associated with a response to therapy intervention, when patients 
exhibited a prominent daily variation of serum BDNF levels at baseline. When this variation 
throughout the day was absent, patients did not respond to partial sleep deprivation. It is possible, that 
an undisturbed circadian regulation of BDNF levels may be responsible for proper adaptation to 
external stressors and therefore maintaining necessary information processing supporting mental 
health. This phenomenon is already known from glucocorticoids, namely cortisol, which is under 
circadian regulation throughout the day (Weitzman, Fukushima et al. 1971; Smyth, Ockenfels et al. 
1997).  
 
In sum, this thesis reports an association of sleep with BDNF and that stress-induced BDNF 
modifications may be modulated by sleep. Furthermore, a diurnal variation of serum BDNF levels 
seems to play an important role in antidepressant therapy response and prediction. Our findings 
support the role of BDNF in adaptation to mood-influencing stressors that could lead to the 
development of depression. This adaption processes may be responsible for different aspects of mood 
regulation and antidepressant-like effect. However, normalization of BDNF during antidepressant 
treatment appears to be confined to some but not all antidepressants and does not correspond with 
amelioration of clinical symptoms (Molendijk, Bus et al. 2011). This could be explained with changes 
in central BDNF concentrations, following reduced insomnia rather than depressive symptoms and 
antidepressants differentially influencing sleep. It is also important to mention, that antidepressants 
differentially influence sleep and therefore sleep wake regulation, specifically insomnia, has to be 
carefully controlled, as well as improvements of sleep during therapy. Possibly there is a unique and 
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bidirectional pathway from illness to recovery that implicates BDNF and synaptic plasticity. However, 
it is still a matter of discussion if the effect of antidepressants on neurogenesis involves always 
neurotrophins. Thus, our preliminary findings suggest that serum BDNF levels are not associated with 
a specific (categorical) diagnosis, but may be associated with insomnia symptoms independent of 
diagnosis (dimensional). In line with this, we suggest that, when analysing serum BDNF levels in 
depressed patients, insomnia symptoms should be carefully controlled, as well as improvements in 
sleep during therapy.  
If stress in general has such a pervasive long-term effect on the brain as well as on the whole body 
there should be some ways to reduce the negative consequences. From the standpoint of the 
individual, it seems obvious that a major goal should be to try to improve sleep quality and quantity as 
well as stress coping strategies, to have a good social support and a positive outlook on life, to have 
positive self-esteem, to maintain a healthy diet, to avoid smoking and to engage in regular moderate 
physical activity (McEwen 2008). In accordance with our data, one can speculate that the 
inconsistence of published data regarding BDNF in depression and therapy response might base on the 
following bias: (i) no monitoring of sleep improvement, only depressive symptomatology, (ii) no 
examination of the existence of a diurnal BDNF profile before therapy intervention and (iii) data for 
single point BDNF assessment after antidepressant therapy is quite variable – from four to eight weeks 
– therefore, it might be that an acute, transient increase of BDND levels is missed. 
Further studies including the monitoring of insomnia, objective sleep measurements, such as sleep 
polysomnography, should be conducted to verify the results of our exploratory investigation and to 
clarify the underlying mechanisms more closely. Especially the underlying BDNF downstream 
signalling pathways and the relationship between BDNF and cortisol with their role to the stress 
hormone system have to be further elucidated. Moreover, the existence of a circadian profile of 
circulating BDNF should be examined, particularly before therapeutic intervention starts.  
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D. Abbreviations 
Abeta    beta-amyloid protein 
ACTH    adrenocorticotropin 
AD    Alzheimer‟s disease 
AKT    serine/threonin kinase 
BDNF    brain-derived neurotrophic factor 
Ca
2+
    calcium 
CaMKII   calcium-calmodulin dependent kinase 
CDS    coding sequence 
CPE    carboxypeptidase E 
CREB    cAMP calcium response element binding protein 
CRF    corticotropin-releasing factor 
DG    dentate gyrus 
DNA    deoxyribonucleic acid 
DSM-IV   Diagnostic and Statistical Manual of Mental Disorders-IV 
ERK    extracellular signal related kinase 
Gab1    Grb-associated binder 1 
GR    glucocorticoid receptor 
Grb2    growth factor receptor bound protein 2 
HPA    hypothalamic-pituitary-adrenal 
IFN    Interferon 
IFN-γ    Interferon γ 
IL-10    Interleukin 10 
IL-1β    Interleukin 1β 
IL-2    Interleukin 2 
IL-6    Interleukin 6 
IRS1/2    insulin receptor substrates ½ 
kDa    kilo Dalton 
LDCV    large dense core vesicles 
MAOI    monoamine oxidase inhibitor 
MAPK    mitogen-activated protein kinase 
MD    Major Depression 
MDD    major depressive disorder 
MEK    MAP/Erk kinase 
MR    mineralcorticoid receptor 
mRNA    messenger RNA 
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NAc    nucleus accumbens 
NGF    nerve growth factor 
NT3    Neurotrophin-3 
NT4    Neurotrophin-4 
p75
NTR    
pan neurotrophin receptor 75 
PFC    prefrontal cortex 
PI3K    phosphatidylinositol-3 kinase 
PKC    protein kinase C 
PLCγ    phospholipase-C-γ 
PVN    paraventricular nucleus 
Raf    Ras associated factor 
Ras    GRP binding protein 
RCT    randomised controlled trial 
REM    rapid eye movement 
RNA    ribonucleic acid 
SD    sleep deprivation 
Shc    Src homology domain containing 
SNP    single nucleotide polymorphism 
SNRI    selective noradrenaline reuptake inhibitor 
SOS    son of sevenless 
SSRI    selective serotonin reuptake inhibitor 
SWA    slow wave activity 
TNF- α    tumor necrosis factor α 
TNF    tumour necrosis factor 
Trk    tropomyosin-related tyrosine kinase 
TrkA    tropomyosin-related tyrosine kinase receptor A 
TrkB    tropomyosin-related tyrosine kinase receptor B 
TrkC    tropomyosin-related tyrosine kinase receptor C 
TSD    total sleep deprivation 
UTR    untranslated region 
VTA    ventral tegmental area 
WHO    World Health Organization 
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